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Summary 
Na
+
/H
+
 exchanger NHE1 is a ubiquitously expressed plasma membrane protein that maintains 
intracellular pH and cell volume by exchanging extracellular Na
+
 for intracellular H
+
. Moreover, 
NHE1 is a scaffold protein that anchors actin filaments and modulates a variety of cellular functions. It 
is described to play role in proliferation, survival and migration of different cell types, but its role in 
endothelial function is not completely understood. To study NHE1 in endothelial and vascular 
functions, appropriate mice models are required. However, the use of the constitutive Nhe1 knockout 
(Nhe1
-/-
) mice for in vivo studies is limited since they grow slowly after birth and develop neurological 
disorders that lead to early death within 3-4 weeks.  
The current work was aimed to examine NHE1’s involvement in endothelial cell proliferation, 
survival and migration, and particularly to analyze if these integrate into complex endothelium 
functions such as angiogenesis. In vitro experiments were performed with primary human umbilical 
vein endothelial cells after silencing NHE1 with small interfering RNA, as well as with primary Nhe1
-
/-
 mouse lung endothelial cells. To obtain an appropriate model for in vivo studies, endothelial cell-
specific Nhe1
-/-
 mice were generated using the Cre/loxP-system by mating Nhe1-floxed mice with the 
VE-Cadherin-Cre-recombinase transgenic mice. The efficiency and specificity of the knockout was 
confirmed by western blot and flow cytometry analysis of cultured mouse lung endothelial cells. 
Angiogenesis was studied in vivo in endothelial cell-specific as well as in constitutive Nhe1
-/-
 mice 
employing the Matrigel plug assay.  
Intracellular pH measurements confirmed that NHE1 is the most important acid-extruder responsible 
for the pH recovery after cytoplasmic acidification of endothelial cells even in bicarbonate-buffered 
solution. Accordingly, when NHE1 was knocked out, steady-state pHi and recovery after cytoplasmic 
acidification were drastically reduced in bicarbonate-free buffered solutions, and pHi recovery was 
significantly decreased even in the presence of bicarbonate. 
Knockdown of NHE1 reduced endothelial cell proliferation by 35% probably by arresting cells in the 
G0/G1 phase of the cell cycle, whereas survival of endothelial cells was not affected. Silencing of 
NHE1 inhibited endothelial cell migration induced by sphingosine-1-phosphate by 32% probably due 
to impaired motility and ability to orient towards the gradient of the stimulant. In line with this, NHE1 
was localized at plasma membrane protrusions in migrating endothelial cells suggesting a role in cell 
migration.  
In agreement with a proliferative and migratory role of NHE1, its involvement in VEGF-induced 
angiogenesis was demonstrated in vitro and in vivo. Downregulation of NHE1 significantly impaired 
VEGF-induced spheroid sprouting by 56%. Moreover, a Matrigel plug assay in constitutive Nhe1
-/-
 
mice revealed an inhibition of VEGF-induced angiogenesis by 22% compared to wild type littermates. 
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However, follow-up experiments with endothelial cell-specific Nhe1
-/-
 mice were not conclusive due to 
unexpected variations in the VEGF-induced angiogenesis in control animals and shall be further 
investigated.  
Together, these findings portray NHE1 as a player in angiogenesis. Results of this thesis also show 
that NHE1 is upregulated during hypoxia (1% O2) through HIF2α-dependent mechanisms, which 
could potentiate NHE1’s role in ischemia-induced angiogenesis. Therefore, in vivo models like hind 
limb ischemia could yet highlight the role of NHE1 in angiogenesis. The generated endothelial cell-
specific Nhe1
-/-
 mice are a valuable tool for future in vivo studies. 
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Zusammenfassung 
Der Na
+
/H
+
-Austauscher NHE1 ist ein ubiquitär exprimiertes Plasmamembranprotein, das den 
intrazellulären pH-Wert (pHi) und das Zellvolumen reguliert, in dem es intrazelluläres H
+
 durch 
extrazelluläres Na
+
 ersetzt. Des Weiteren ist NHE1 ein Scaffold-Protein, das Aktinfilamente verankert 
und dadurch eine Vielzahl zellulärer Funktionen reguliert. NHE1 spielt in verschiedenen Zelltypen 
eine Rolle bei Proliferation, Überleben und Migration, aber seine Rolle in Endothelzellen ist noch 
nicht vollständig verstanden. Um NHE1 im Zusammenhang mit endothelialen und vaskulären 
Funktionen untersuchen zu können, sind geeignete Mausmodelle vonnöten. Die Verwendung von 
konstitutiven Nhe1-knockout (Nhe1
-/-
)-Mäusen für in-vivo-Studien ist allerdings begrenzt, da sie nach 
der Geburt langsam wachsen und neurologische Funktionsstörungen ausbilden, die innerhalb von 3-4 
Wochen zu einem frühen Tod führen. 
Ziel der vorliegenden Arbeit war es, die Bedeutung von NHE1 für endotheliale Funktionen wie 
Proliferation, Überleben und Migration zu untersuchen und dabei insbesondere zu analysieren, ob 
komplexe Prozesse wie die Angiogenese beeinflusst werden. In-vitro-Experimente wurden mit 
primären human umbilical vein endothelial cells (HUVEC), in denen NHE1 mit small interfering 
RNA (siRNA) herunterreguliert wurde, und in primären Nhe1
-/-
 Endothelzellen aus der Mauslunge 
durchgeführt. Um ein geeignetes Modell für in-vivo-Studien zu erhalten, wurden mit Hilfe des 
Cre/loxP-Systems endothelzellspezifische Nhe1
-/-
-Mäuse generiert, indem Nhe1-gefloxte Mäuse mit 
VE-Cadherin-Cre-Rekombinase-transgenen Mäusen verpaart wurden. Die Effizienz und Spezifität des 
knockouts wurde in Western-Blot- und Durchflusszytometrie-Analysen von aus den Mäusen 
präparierten primären Endothelzellen bestätigt. Die Angiogenese wurde in vivo mit Hilfe des Matrigel-
Plug-Assays sowohl in endothelzellspezifischen als auch in konstitutiven Nhe1
-/-
-Mäusen untersucht. 
Messungen des pHi bestätigten, dass NHE1 der wichtigste Protonen-Exporter für die Erholung des pH-
Werts nach zytoplasmatischer Ansäuerung von Endothelzellen ist, unabhängig davon, ob Bicarbonat 
im Puffersystem vorhanden ist. Wurde NHE1 depletiert, waren sowohl der basale pHi als auch die 
Erholung des pHi-Werts nach Ansäuerung in Bicarbonat-freien Pufferlösungen drastisch reduziert. Die 
pHi-Erholung war auch in Anwesenheit von Bicarbonat noch signifikant vermindert.  
Der knockdown von NHE1 verminderte die endotheliale Proliferation um 35 %, vermutlich aufgrund 
eines Zellzyklusarrests in der G0/G1-Phase. Dagegen war das Überleben der Endothelzellen nicht 
beeinflusst. Die Sphingosin-1-Phosphat (S1P)-induzierte Endothelzellmigration wurde durch die 
Herunterregulierung von NHE1 um 32 % reduziert, was auf einer eingeschränkten Zellmotilität und 
der verminderten Fähigkeit, sich entlang des Stimulus-Gradienten auszurichten, beruht. NHE1 ist an 
Fortsätzen der Plasmamembran migrierender Zellen lokalisiert, was für eine Beteiligung an der 
Migration spricht. 
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In Übereinstimmung mit der Rolle von NHE1 bei der Proliferation und Migration konnte die 
Beteiligung von NHE1 bei der vascular endothelial growth factor (VEGF)-induzierten Angiogenese 
in vitro und in vivo gezeigt werden. Die Herunterregulierung von NHE1 hemmte die VEGF-induzierte 
Sprossbildung signifikant um 56 %. Im Matrigel-Plug-Assay in konstitutiven Nhe1
-/-
-Mäusen wurde 
die VEGF-induzierte Angiogenese im Vergleich zu den Wildtyp-Geschwistern um 22 % gehemmt. 
Jedoch waren nachfolgende Experimente in endothelzellspezifischen Nhe1
-/-
-Mäusen aufgrund 
unerwarteter Schwankungen der VEGF-induzierten Angiogenese in Kontrolltieren nicht eindeutig und 
müssen weiter untersucht werden. 
Zusammengefasst stellen die Daten dieser Arbeit NHE1 als ein Mediator der Angiogenese dar. Die 
Ergebnisse zeigen auch, dass NHE1 unter Hypoxie (1 % O2) in einem HIF2α-abhängigen Weg 
hochreguliert wird, was auf eine Rolle von NHE1 bei Ischämie-induzierter Angiogenese hindeutet. In-
vivo-Modelle wie das hind limb-Ischämiemodell könnten die Rolle von NHE1 bei der Angiogenese 
weiter herausstellen. Die generierten endothelzellspezifischen Nhe1
-/-
-Mäuse sind ein wertvolles 
Modell für weitere in-vivo-Studien. 
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Përmbledhje (in albanian) 
NHE1 është një transportues jonik që gjendet në membranën qelizore, i cili përmes këmbimit të një 
joni Na
+
 jashtëqelizorë me një jon H
+
 brendaqelizorë luan një rol të rëndësishëm  në ruajtjen e pH-së 
dhe vëllimit të qelizës. Gjithashtu, kjo proteinë në sajë të kontaktit fizik me filamentet e aktinës, që 
janë pjesë e skeletit qelizorë, mund të ndikojë në një mori funksionesh qelizore. Hulumtimet 
shkencore kanë treguar përfshirjen e tij në shumimin, mbijetesën dhe migrimin e shumë lloje qelizash, 
por ende nuk njihet mirë funksioni i këtij transportuesi në qelizat endoteliale.  Për të kuptuar më 
shumë rreth rolit të këtij transportuesi në sistemin kardiovaskularë, është i nevojshëm përdorimi i 
minjve të modifikuara gjenetikisht. Megjithatë, në rastin e transportuesit NHE1, përdorimi i  minjve, 
në të cilët gjeni që kodon këtë protein është i çaktivizuar në të gjitha indet (Nhe1
-/-
), është i kufizuar 
pasi  minjtë e këtij tipi karakterizohen me ngecje në zhvillim dhe çrregullime nervore që çojne në 
vdekje të hershme brenda 3-5 javësh pas lindjes. 
Me qëllim të ekzaminimit të rolit të mundshëm të këtij transportuesi jonik në rritjen, mbijetesën, 
mirgrimin e qelizave endoteliale, si dhe analizimi i proceseve komplekse vaskulare si angiogjeneza, 
gjatë këtij projekti janë kryer eksperimenteve in vitro me qeliza endoteliale të njeriut nga kordoni 
umbilikal dhe qeliza endoteliale nga mushkritë e minjve. Në rastin e qelizave humane, manipulipi në 
shprehjen e proteinës është bërë përmes ARN-ve të shkurtra ndërhyrëse, ndërsa në rastin e qelizave 
nga minjtë, ato origjinojnë direkt nga gjenotipi Nhe1
-/-
. Përvec këtyre, për të studiuar përfshirjen e 
NHE1 në procesin e angjiogjenezës brenda organizmit (in vivo) ishte i novojshëm gjenerimi i modelit 
në minjë, ku gjeni është çaktivizuar specifikisht vetëm në qelizat endoteliale. Kjo u arrit përmes 
sistemit Cre/loxP pas kryqëzimit të minjëve transgjenik Nhe1-flox me minjë VE-Cadherin-Cre-
recombinase. Më tej, efikasiteti dhe specificiteti i ndryshimit gjenetik të gjenit Nhe1 u vërtetua përmes 
metodave Western blot dhe Flow cytometry.  Sudimi i procesit të angjiogjenezës brenda organizmit u 
realizua duke përdorur metodën Matrigel plug assay. 
Të dhënat mbi rregullimin pH-së brendaqelizore nxorën në pah rolin e rëndësishëm të këtij 
transportuesi në qelizat endoteliale. Në mungesë të proteinës NHE1, qelizat e kanë të kufizuar aftësinë 
për të mbajtur pH-në bazale në vlerat normale, e sidomos aftësinë për të rikuperuar pH-në 
citoplazmatike pas acidifikimit.  
Përmes eksperimenteve in vitro gjithashtu u konstatua se mungesa e NHE1 çon në reduktim të 
shumimit qelizorë për gati 35%, me gjasë për shkak të frenimit të kalimit të qelizave nga faza Go në 
fazën G1 te ciklit qelizorë. Eksperimente të ngjashme treguan se NHE1 nuk ndikon në mbijetesën 
qelizore, por ai gjithsesi ndikon në lëvizjen ose migrimin qelizorë. Mungesa e proteinës NHE1 u 
shoqërua me reduktim të migrimit qelizorë për afërsisht 32% nën stimulimin me sfingosinë-
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monophosphatit. Në përputhje me këtë, përmes ngjyrimit citokimik me antitrupa, NHE1 u gjet të 
vendoset tek protruzionet e qelizave migruese. 
Marrë parasysh rolin e proteinës NHE1 në shumimin dhe migrimin e qelizave endoteliale, përmes 
eksperimenteve in vitro dhe in vivo kjo protein është gjetur të jetë e rëndësishme gjatë angjiogjenezës 
pas stimulimit me VEGF. Ulja e nivelit të proteinës NHE1 rezultoi në zvogëlim të angjigjenzës për 
afro 56% in vitro (spheroid assay). In vivo, mungesa e plotë e NHE1 në të gjitha indet e miut rezultoi 
në inhibim të angjiogjenzës për rreth 22% (Matrigel plug assay). Megjithatë, angjigjeneza në minjt ku 
Nhe1 ishte çaktivizuar specifikisht në qelizat endoteliale duhet të analizohet më tutje, për arsye se 
VEGF nuk arriti të stimulojë angjiogjenezën as në minjët kontroll (wildtype).  
Si përfundim, NHE1 duket të jetë një faktor i rëndësishëm gjatë angjiogjenezës. Eksperimente të tjera 
gjatë këtij projekti tregojnë se shprehja e NHE1 në nivelin proteinorë rritet në kushte të hipoksisë (1% 
O2) përmes mekanizmave të varura nga HIF2α. Prandaj, Hindlimb ischemia si një model më 
fiziologjik për të studiuar angjiogjenezën in vivo, do të mund të nxirrte më shumë në pah rëndësinë e 
NHE1 gjatë këtij procesi. Në përgjithësi, minjtë e krijuar gjatë këtij projekti, ku Nhe1 është 
inaktivizuar specifikisht në qelizat endoteliale, janë një model i vlefshëm për studime të ndryshme in 
vivo. 
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1 Introduction 
1.1 Endothelium and angiogenesis 
Endothelial cells [2, 3] form a monolayer, which constitutes the inner lining of blood vessels. The 
endothelium is attached to the basal lamina in capillaries and is surrounded by smooth muscle cells in 
arterioles and venules, as well as by connective tissue in larger vessels. It is in direct contact with the 
circulating blood and acts as a semipermeable barrier that mediates gas and nutrient exchange with the 
surrounding tissues. Moreover, the endothelium is a major regulator for vascular tone, blood clotting, 
angiogenesis and inflammation. Dysfunction of endothelial cells results and/or contributes to many 
pathophysiological processes including ischemia, thrombosis, atherosclerosis, diabetes and 
hypertension.  
Endothelial cells arise from the mesoderm. They differentiate from hemangioblasts, as do 
hematopoietic cells, and exhibit heterogeneity regarding morphological and physiological 
characteristics. Endothelial cells display phenotypic variability not only with respect to the individual 
blood vessels such as arteries, veins, and capillaries, but also with respect to vascular beds of different 
organs depending on the surrounding tissue. Vascular development starts with de novo vasculogenesis 
in utero while the remodeling and expansion into an organized vascular tree from preexisting blood 
vessels ensues through angiogenesis [93]. 
 
Figure 1-1: Development of the vascular tree 
Endothelial cells arise from angioblasts (A), which assemble to form de novo primary vascular tree through the 
process of vasculogenesis during the intrauterine life (B). Angiogenesis is the formation of new blood vessels 
from preexisting ones and can occur through sprouting or intussesceptive vessel growth (C). Modified from [2]. 
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Angiogenesis occurs throughout life. Physiological angiogenesis maintains tissue´s metabolic needs 
by ensuring that cells are no more than 50-100 µm distant from capillaries. It is involved in the 
physiology of development, reproduction, wound healing, and inflammation. Numerous diseases are 
characterized and/or caused by abnormal, excessive or conversely by insufficient angiogenesis or 
vessel regression. Therefore, controlling this process is therapeutically important: stimulating 
angiogenesis improves ischemic conditions and wound healing whereas inhibition of angiogenesis is 
relevant in cancer, ophthalmic conditions, rheumatoid arthritis, and other diseases. 
Angiogenesis can proceed in distinct patterns. Quiescent endothelial cells are activated by angiogenic 
factors released from the surrounding hypoxic tissue and invade to build a vascular bed into the 
previously devoid tissue. In this process vascular endothelial growth factor (VEGF) is essential. The 
sprouting angiogenesis involves selection of an endothelial tip cell that protrudes towards the tissue 
and digests the extracellular matrix along the way [4]. The tip cell is followed by proliferating 
endothelial stalk cells that elongate the sprout while the capillary lumen becomes functionally 
perfusable as opposing tip cells meet each other. 
Different to sprouting, intussusceptive (splitting) angiogenesis splits a single vessel in two as the wall 
extends into the lumen without immediate endothelial proliferation and migration. In both cases, the 
process is coordinated with pericytes, fibroblasts and smooth muscle cells. Recruitment of the 
pericytes and deposition of the extracellular matrix stabilizes and maturates the newly formed vessel. 
 
Figure 1-2: Sprouting angiogenesis 
VEGF and other growth factors released from the ischemic tissue mediate the selection of the tip cell, which 
migrates towards the tissue devoided of blood vessels. The stalk cells proliferate and follow the tip cell. The new 
blood vessel is formed after the different tip cells meet each other while the recruited pericytes and the 
deposition of extracellular matrix stabilize the newly formed vessel. Modified from [2]. 
1.1.1 VEGF receptor 2 (VEGFR2) signaling in angiogenesis 
VEGF is a central growth factor during angiogenesis. It acts on endothelial cells via three tyrosine 
receptor kinase receptors (VEGFR1-3) with VEGFR2 being the most important one. VEGF binding to 
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VEGFR2 leads to receptor homodimerization and autophosphorylation that activates several signaling 
pathways important for angiogenesis. VEGFR2 signaling promotes cell survival and initiates 
migration through activation of protein kinase AKT, endothelial nitric oxide synthase (eNOS) and the 
small GTPase Rac. It also regulates cell metabolism, migration and proliferation via phospholipase C 
(PLCγ)-dependent activation of AMP-activated protein kinase (AMPK), eNOS and p42/44 mitogen-
activated protein kinases (MAPK), respectively. VEGFR2 activation can also initiate cell migration 
through p38MPAK and activate focal adhesion kinase (FAK). 
VEGFR2 signaling enables the tip cell selection, which is a precisely tuned process that allows normal 
development of vasculature. Tip cells are usually the ones exposed to the highest concentration of 
VEGF. The membrane of the tip cell develops small projections called filopoida, which are rich in 
VEGFR2 and can therefore sense the gradient of VEGF. VEGF stimulation of the tip cell induces 
expression of the Delta-like-4 (DLL4) ligand. Subsequently, direct cell-cell contacts enable DLL4 of 
the tip cell to bind to the notch receptor of neighbouring cells, thereby reducing VEGFR2 expression 
and leading to the stalk cell phenotype, which is less migratory and more proliferative and ensures the 
stability of the new sprout [5, 6].  
 
Figure 1-3: Vascular endothelial growth factor (VEGF) in sprouting angiogenesis 
Panel (A) shows VEGFR2 signaling pathway in endothelial cells, which leads to tip cell selection and stalk cell 
induction as depicted in (B). AKT: protein kinase B; eNOS: endothelial nitric oxide synthase; FAK: focal adhesion 
kinase; MAPK: mitogen-activated protein kinase; PI3K: phosphatidylinositol-3-kinase; PLCγ: phospholipase C-γ. Modified 
from [2, 5]. 
1.1.2 Sphingosine-1-phosphate (S1P) in angiogenesis 
S1P is an important factor in angiogenesis. It is especially involved in the regulation of endothelial cell 
migration but also in endothelial survival and proliferation. It is generated from the plasma membrane 
sphingolipids, and endothelial cells and activated platelets are a major source. Among the five G-
protein-coupled S1P receptors (S1P1-5), S1P1 and S1P3 are the most abundant in endothelial cells [7]. 
S1P receptors trigger downstream activation of Rac and p38MAPK, which regulate cytoskeletal 
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rearrangements and focal adhesion turnover through FAK and Src activation. In addition, activation of 
S1P1 induces calcium signaling and calmodulin-mediated activation of eNOS through the 
phosphoinositide 3-kinase β (PI3Kβ)/PLC pathway. S1P can also activate VEGFR2 in endothelial 
cells in the absence of VEGF through receptor crosstalk (receptor transactivation) leading to eNOS 
and Rac activation through PI3Kα/AKT signaling pathway, as well as to activation of CrkII, an 
adaptor molecule of tyrosine kinases involved in membrane rearrangements and cell motility. 
Together, focal adhesions turnover, eNOS and Rac activation highlight S1P as an important mediator 
of endothelial cell migration and angiogenesis [8, 9]. In line with this, S1P strongly potentiated VEGF-
induced angiogenesis in vivo in mice using the Matrigel plug assay [7]. Of note, S1P might be one of 
the main migration-inducing-factor in fetal calve serum used in experimental culture conditions [10]. 
1.2 Homeostasis of intracellular pH and cell volume 
The homeostasis of intracellular and extracellular ion concentrations is the basis of physiological 
processes. Cells maintain ionic gradients across the semi-permeable lipid cell membrane by means of 
highly specialized proteins: transporters, channels, and pumps. This involves optimal control of the 
concentration of intracellular protons and osmolyte concentration, i.e. of intracellular pH (pHi) and cell 
volume, respectively.  
The concentration of hydrogen ions affects the milieu in which metabolic reactions occur. Moreover, 
the protonation state of weak acid and base moieties defines the conformation and function of all 
proteins [11]. Consequently, enzymatic reactions are especially sensitive to pH alterations. For 
instance, a decrease of 0.2-0.3 pH units in the intracellular pH almost completely inhibits the activity 
of phosphofructokinase-1 (PFK-1) [12] and effectively reduces glycolysis [13]. Other proteins 
particularly sensitive to slightest changes in pHi include: ion channels [14], G-protein-coupled 
receptors [14], and enzymes (e.g. eNOS [15-17] and endothelin-converting enzyme [18]). Intracellular 
pH usually refers to the pH in the cytoplasm, which can be very different from the pH in each cellular 
organelle [19]. 
In addition to the intrinsic cell activity that generates mainly acid equivalents, the extracellular 
surrounding constantly challenges the pHi. Although drastic deviations of local and systemic 
extracellular pH are efficiently counteracted, homeostatic mechanisms may become insufficient. For 
instance, metabolic or respiratory acidosis cause systemic pH disturbances whereas severe ischemia 
[20] or malignant tumors [21] may result in dramatic local decrease of extracellular pH. 
Physiological steady-state intracellular pH (pHi ~7.2 pH units) is slightly lower than extracellular pH 
(pHe ~7.3-7.4 pH units). This is a consequence of acid production during cellular metabolism and the 
negative plasma membrane potential (~-60 mV, [22]), which drives passive H
+
 uptake and efflux of 
HCO3
-
 and OH
-
. Intracellular pH follows the changes in extracellular pH in the same direction by 
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~30% [22] and is more sensitive to respiratory than metabolic extracellular acid-base disturbances [14, 
23-25]. Nevertheless, pHi is much higher than calculated from electrochemical H
+
 distribution across 
the plasma membrane (~6.2 pH units, [26]), which means that acid-extruding processes are very active 
at steady-state conditions. 
Cells maintain optimal pHi through various mechanisms [22, 27]. Acute perturbations are rapidly 
buffered by the HCO3
-
/CO2 buffering system [22], and to some extend by weak acids and bases (e.g. 
side chains of amino acids, phosphate groups). Buffers are able to donate or accept protons and 
neutralize alkaline or acid load, respectively. Buffering power, however, has no effect on the steady-
state pHi. Various transporters and pumps set and maintain long-term steady-state pHi by extruding or 
importing proton equivalents [22] usually by electroneutral ion exchange. Most acid-extruders are 
secondary active and require Na
+
. These include Na
+
/H
+
 exchangers (NHEs), Na
+
/HCO3
-
 
cotransporters (NBCs) and Na
+
 driven Cl
-
/HCO3
-
 exchanger (NCBEs). On the other hand, Cl
-
/HCO3
-
 
anion exchangers (AEs) use the electrochemical gradient of Cl
-
 as the driving force to extrude HCO3
-
 
and indirectly load the cells with acid. 
 
Figure 1-4: Mechanisms involved in cell acid loading and extrusion 
Cells are acidified by metabolism and passive movement of ions. The latter includes entry of H
+
 and exit of OH
-
 
and HCO3
-
 across the lipid membrane. Various transporters, channels and pumps at the plasma membrane 
regulate pHi by extruding or loading cells with acid equivalents. NHE: sodium hydrogen exchanger, NBC: 
sodium bicarbonate cotransporter, NCBE: sodium-driven chloride bicarbonate exchanger, V-ATPase: vacuolar 
ATP-driven H
+
 pump, AE: anion exchanger. Figure modified from [22]. 
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Similar to intracellular pH, cell volume homeostasis is crucial for the integrity and cellular functions. 
However, cell volume is constantly challenged by changes in the surrounding osmolarity and the 
intracellular composition, which force water to move in and out of the cell and exert mechanical 
pressure. The water-permeable plasma membrane forms invaginations upon loss of pressure and can 
stretch to dampen increased osmotic pressure, but it is fragile to withstand high pressure. Under 
temporary anisotonic conditions cells activate a number of channels and transporters to avoid 
excessive alterations of their volume. Shrinkage is countered through regulatory volume increase 
(RVI) achieved by net influx of NaCl and organic solutes, while swelling triggers regulatory volume 
decrease (RVD) through net efflux of KCl and organic solutes, and therefore water. The NHE isoform 
1 (NHE1) participates in RVI by mediating net NaCl influx when activated in parallel with Cl
-
/HCO3
-
 
anion exchangers (AE) [28, 29]. 
 
Figure 1-5: Mechanisms involved in cell volume regulation 
(A) Under isotonic conditions the Na
+
/K
+
 ATPase is the most important mechanism that maintains volume 
homeostasis and the electrochemical gradients of Na
+ 
and K
+
. Changes in extracellular osmolarity (B) disturb 
cell volume: hypertonicity causes water efflux and shrinking of the cell, whereas hypotonicity leads to water 
influx and cell swelling. (C) Both stresses are counteracted by mechanisms that lead to NaCl uptake or KCl 
release respectively. NHE: sodium hydrogen exchanger, AE: anion exchanger, NCC: sodium chloride 
cotransporter, NKCC: sodium potassium chloride cotransporter, KHE: potassium hydrogen exchanger. 
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1.3 Sodium/hydrogen exchanger NHE1 
The Na
+
/H
+
 exchanger NHE1 is a ubiquitously expressed plasma membrane protein [30] that catalyses 
1:1 electroneutral exchange of intracellular H
+
 for extracellular Na
+
. As a secondary active transporter, 
it gains the energy from the inwardly directed Na
+
 gradient to extrude H
+
 against the concentration 
gradient. It therefore regulates intracellular pH (pHi) – important for proper functioning of all proteins 
– and cell volume by net NaCl influx (and therefore water) when NHE1 acts jointly with Cl- 
transporters. 
NHE1 has been characterized in several human pathologies. Over-activation is related to 
ischemia/reperfusion injuries, diabetes-associated vascular dysfunction, and atherosclerosis [31, 32]. 
Additionally, the putative role of NHE1 in supporting tumor progression has attracted major attention 
[33]. Inhibition of NHE1 was proven beneficial in animal studies of these pathologies and has 
therefore many potential pharmacological indications. 
Moreover, many processes that endothelial cells undergo during angiogenesis are potentially 
supported by NHE1, including migration [34], proliferation and ECM degradation. Therefore, it is 
important to understand the role of NHE1 in endothelial function and angiogenesis, since it may 
represent a pharmacological target to treat excessive angiogenesis. 
1.3.1 NHE1 protein 
NHE1 belongs to the SLC9A family of ion transporters [35]. Overall, nine isoforms are described in 
mammals so far, termed NHE1-9. Isoforms show different tissue distribution and intracellular 
localization: whereas NHE1-5 locate at the plasma membrane and exchange H
+
 for Na
+
, NHE6-9 are 
found at the membranes of intracellular organelles and exchange H
+
 for K
+
 [19, 36]. 
The human NHE1 protein comprises 815 amino acids with a molecular mass of approximately 91 
kDa. Since functional NHE1 is glycosylated, in SDS-PAGE it runs as a protein of approximately 110 
kDa [37]. NHE1 can be separated into two functional domains. The N-terminal domain contains 12 
transmembrane α-helices and mediates the ion exchange activity. The hydrophilic intracellular C-
terminal domain regulates the exchange activity and has a scaffold function [38]. Importantly, NHE1 
can bind to the actin filaments and anchor them to the plasma membrane. This interaction is mediated 
by actin binding proteins ezrin, radixin, and moesin (ERM) [39]. 
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Figure 1-6: Schematic overview of the NHE1 protein  
NHE1 protein contains two functional domains: The N-terminal domain containing 12 transmembrane α-helices 
mediating ion exchange, and the C-terminal cytoplasmic domain that binds several proteins and is 
phosphorylated at different serine and tyrosine sites. NHE1 can anchor actin through ERM binding (ezrin, 
radixin, moesin). Modified from [35, 40]. 
1.3.2 Regulation of NHE1 activity 
Two major factors determine the ion exchange rate of NHE1: the intracellular concentration of H
+
 
([H
+
]i) and changes in cell volume. NHE1’s activity can affect both simultaneously, since extrusion of 
H
+
 increases pHi while the influx of Na
+
, if coupled to Cl
-
 influx, increases intracellular osmolarity and 
cell volume. Therefore, NHE1 can optimize pHi and cell volume simultaneously or prioritize one to 
the expense of the other. Under resting conditions, at physiological steady-state pHi, bicarbonate-
dependend transporters (NBCs and NCBEs) are considered as major long-term regulators of pHi. If 
intracellular pH drops below a certain threshold, NHE1 allosterically senses the increase in [H
+
]i and is 
rapidly activated to recover pHi to the physiological steady-state range [26]. This threshold is prone to 
changes, and depends on the affinity of NHE1 for intracellular H
+
. Signals from receptor-tyrosine 
kinases [41], G-protein-coupled receptors [42], and integrin receptors [43, 44] modulate NHE1’s 
affinity for H
+
 through phosphorylation, binding of regulatory proteins or inducing other 
conformational changes in the C-terminal domain. Although NHE1 forms homodimers, it is unclear 
whether the functional unit is the dimer or rather the monomer [26]. As for the ion exchange activity, 
it is proposed that monomers are capable of catalyzing ion exchange at acidic pHi whereas the 
dimerization is needed for ion exchange at neutral pHi range [45]. 
1.4 Cellular functions of NHE1 
Co-ordination between ion exchange, actin anchoring and scaffold function enables NHE1 to play 
crucial role in fundamental cellular processes including cell shape and adhesion [39], migration, 
proliferation and survival [14]. 
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1.4.1 Migration 
Cell migration is a fundamental process in multicellular organisms that among others ensures proper 
immune response and tissue regeneration. Cells sense and respond to migratory stimuli that are either 
soluble (chemotaxis), immobilized ligands (haptotaxis), or mechanical (mechanotaxis) [4]. VEGF and 
basic fibroblast growth factor (bFGF) are strong chemotactic stimuli, while integrins bound to 
extracellular matrix (ECM) are involved in haptotaxis of endothelial cells. Mechanotaxis triggers 
mechanotransducion and is therefore important for shear stress induced endothelial cell migration [46]. 
During directed movement, the cytoskeleton is continuously remodeled and provides the necessary 
mechanical force that enables cell polarization into dynamic rear and front edge [4, 47]. Filopodia are 
generated from the membrane and sense motile stimuli. At the front, focal adhesions dynamically form 
and destabilize allowing lamellipodia and pseudopodia-like protrusions to adhere and pull the cell 
body forward. Simultaneously, stress fibers lead to destabilization of previous adhesions and retraction 
at the rear edge. 
 
The cell membrane is continuously rearranged throughout migration. It links the cytoskeleton to the 
extracellular matrix and allows the mechanical changes to occur. Ion transporters participate in 
anchoring the cytoskeleton to the plasma membrane [48]. In particular, NHE1’s ability to anchor actin 
filaments to the membrane through interaction with ERM proteins makes it an important player in 
regulating the function and morphology of the moving cell. Through binding to ERM, NHE1 is 
restricted to primary lamellipodia. Accordingly, an NHE1 mutant unable to bind ERM was distributed 
diffusely and the cell produced extensions in all directions [49]. Restricting NHE1 at the leading edge 
enables local pHi gradients to support scaffolding protein interactions [50-52] while the osmotic 
activity can provide mechanical force to push protrusions forward [53, 54]. Additionally, NHE1 
promotes invasion as local proton extrusion lowers the extracellular pH near the membrane [55] and 
optimizes metalloproteinase digestion of ECM [56]. Moreover, cytoskeleton anchoring through NHE1 
was shown to be required for focal adhesion assembly [39, 52], whereas the ion exchange function of 
Figure 1-7: The cycle of cell 
motility 
After sensing the migratory stimulus (1), 
the cell membrane protrudes forward (2) 
and adheres (3) to pull the cell body 
forward (4) while the rear end retracts (5). 
Adapted from [1]. 
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NHE1 was involved in remodeling focal adhesions. Inability to remodel focal adhesions led to 
insufficient disassembly of the formed adhesions resulting in elongated tails that failed to retract and 
slowed down the overall cell movement [49]. NHE1 ion exchange activity was also necessary to 
disassemble actin stress fibers and to assemble cortical F-actin clusters at focal adhesions [57]. 
Moreover, polarized ion exchange by NHE1 was able to create whole cell pHi gradients along the axis 
of movement [58], which were flattened after inhibiting NHE1 [55, 59]. 
Taken together, NHE1 supports chemotaxis [53, 60] by regulating cell polarization, pushing 
protrusions forward, remodeling adhesions both at the rear and front as well as promoting digestion of 
ECM. NHE1 inhibition may not alter random cell mobility, but may slow down the cell and limit 
efficient movement towards the stimulus. 
 
Figure 1-8: Polarization of the cell during migration 
(A) NHE1 is translocated to the leading edge, which increases intracellular pH and lowers extracellular pH near 
the membrane. NHE1 might also be active at the rear edge aiding focal adhesion disassembly. (B) NHE1 activity 
at the leading edge optimizes the activity of extracellular proteases to digest the extracellular matrix. Modified 
from [27]. 
1.4.2 Proliferation and survival 
Several studies highlight the importance of NHE1 for cell proliferation not only due to its ion 
exchange activity that extrudes metabolically-produced protons and mediates the volume increase 
during mitosis [61], but probably also due to modulating signaling and functional states of cells [30]. 
In contrast to migration, proliferation is influenced more by global rather than local pHi changes. 
NHE1-dependent pHi regulation is shown to affect G2/M entry and transition [62] and NHE1 
inhibition arrested pulmonary artery smooth muscle cells in G0/G1 phase of the cell cycle [63]. 
Unfortunately, the role of NHE1 in proliferation is often studied under bicarbonate-free conditions 
[64-66], which blocks other crucial pHi regulatory mechanisms (e.g. NBCs and NCBEs) and 
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complicates data interpretation. Thus, studies indicate a permissive rather than obligatory role of 
NHE1 in cell proliferation [66-68]. 
Similarly, NHE1 promotes survival by simultaneously counteracting the drop in pHi and cell shrinkage 
[69, 70], both hallmarks of apoptosis [28, 71], as well as by activating AKT-dependent survival 
pathways through recruitment of ERM [72]. 
1.5 NHE1 in endothelium 
NHE1 has been described to localize at the basolateral side of the plasma membrane of endothelial 
cells [73, 74]. It is suggested to be the only relevant NHE isoform expressed in endothelial cells [73, 
75] and to represent together with the Na
+
/HCO3
-
 cotransporter NBCn1 the most important Na
+
-
dependent acid-extruders regulating pHi of endothelial cells [17, 68]. 
In vivo studies have demonstrated NHE1’s involvement in complex endothelial cell functions such as 
endothelium-dependent vessel relaxation, barrier function, and ischemia/reoxygenation damage. 
Generally, studies suggest that NHE1 exhibits a homeostatic function in endothelial cells under low 
stress conditions but contributes to dysfunction under severe stress conditions.  
1.5.1 NHE1 in endothelial-dependent vasorelaxation 
Endothelial cells actively control vascular tone by producing vasoactive factors that change the 
contraction state of vascular smooth muscle cells. Endothelium-derived nitric oxide (NO) is produced 
by eNOS and is a well-known inducer of vessel relaxation. Although eNOS activity is regulated by 
Ca
2+
 signaling and protein phosphorylation, its enzymatic activity is intrinsically sensitive to the 
surrounding pH. Slight shifts from the physiological pHi towards higher or lower values significantly 
reduce NO synthesis [15, 17]. Importantly, NHE1-dependent pHi regulation of endothelial cells was 
shown to alter eNOS activity in vitro [21] and physiological activation of NHE1 supported NO-
mediated vessel relaxation in vivo [20]. Surprizingly, constitutive Nhe1
-/-
 mice had a lower arterial 
blood pressure compared to wild type littermates by 25 mmHg [17]. Although arterioles from these 
mice had thinner walls that produced less contraction force, it is yet to be confirmed if this is the cause 
or a consequence of reduced arterial blood pressure. Interestingly, constitutive Nhe1
-/-
 mice were also 
protected from hypoxia-induced vascular remodeling and pulmonary hypertension [76]. 
1.5.2 NHE1 and vascular pathologies 
Whereas NHE1 was shown to support physiological endothelium-dependent vessel relaxation, in 
pathological conditions NHE1 could contribute to tissue damage since genetic inactivation or 
pharmacological inhibition of NHE1 preserved organ function. Inhibition of NHE1 improved heart 
functions and endothelium-dependent coronary vessel relaxation in studies with rodents, as shown for 
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cardiac ischemia [77, 78] and streptozotocin-induced diabetic cardiomyopathy [79, 80]. NHE1 
inhibitors failed to produce similar results in clinical trials though, and resulted in increased mortality 
due to cerebrovascular events [81-84]. Consequently, despite marginal benefits in subgroups of 
patients, the development of NHE1 inhibitors to treat ischemic cardiomyopathies has been 
discontinued. 
The molecular mechanisms involving NHE1 with these pathologies remain unclear. It has been 
suggested that overstimulation of NHE activity provokes accumulation of intracellular Na
+
, which in 
turn activates reverse-mode Na
+
/Ca
2+
 exchange, leading to an influx of Ca
2+
 into the cells and [Ca
2+
]i 
overload [85]. This in turn would activate several Ca
2+
-dependent processes contributing to 
pathological alterations. In line with this, NHE1 inhibition was shown to decrease ICAM-1 expression 
in hypoxic/reoxygenated coronary microvascular endothelial cells, which could potentially reduce 
leukocyte-induced tissue damage ([86]). During ischemia, the tissue becomes hypoxic and 
extracellular pH drops. The acidic microenvironment may inhibit kinetic properties of NHE1. ROS, 
which are elevated during both hypoxia and reoxygenation, have also been linked to NHE1 regulation. 
O
2-
 has been shown to increase expression and H2O2 to decrease expression of NHE1 [87] and to 
inhibit the ion exchange activity [75]. Moreover, hypoxia was shown to upregulate NHE1 in 
endothelial cells [73], possibly through HIF1-dependent mechanisms [88, 89]. Inhibition by H2O2 
could serve as a defense mechanism against Ca
2+
 overload mediated by NHE1 during 
ischemia/reperfustion [14]. 
Animal models for stroke also show the detrimental situation of active NHE1 during ischemia and 
after reperfusion. Here, NHE1 was possibly involved in the barrier function of the endothelium by its 
ability to regulate cell volume. After middle cerebral artery occlusion stroke model in rats, 
pharmacological inhibition of NHE1 reduced brain edema by preserving the function of the blood 
brain barrier [90, 91]. Applying the same stroke model, heterozygous Nhe1 knockout mice developed 
smaller infarct with preserved neurological function in the brain compared to their wild type 
littermates [92]. Pharmacological inhibition of NHE1 with cariporide also inhibited induction of 
microvascular leakage by methylglyoxal, a proinflamatory side-product of metabolism encountered 
during diabetic angiopathy [93]. 
1.6 Constitutive Nhe1 knockout mouse model 
Genetic and pharmacological inhibition have been used to study NHE1 in physiological and 
pathological situations. Constitutive Nhe1 knockout mouse model (Nhe1
-/-
) was first generated in 1999 
by Bell et al. (1999) [94] and has ever since been a useful model for in vivo characterization of NHE1. 
The constitutive Nhe1
-/-
 mice develop normally at first, but after the second postnatal week they grow 
slowly and are characterized by a severe neurodegeneration. The mice show increased mortality prior 
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to weaning, likely due to seizures [94]. Therefore, the severe phenotype and early death make the 
constitutive Nhe1
-/-
 mice unsuitable for many in vivo studies and tissue-specific knockout models are 
required to characterize specific functions of NHE1 in vivo. 
1.7 The aim of the study 
NHE1 has been previously suggested to be involved in endothelial cell functions in vitro and in vivo, 
although only few data exist about its influence on complex endothelial functions. So far, genetic and 
pharmacological inhibition have been used to study NHE1 in physiological and pathological 
situations. However, due to the severe phenotype of the constitutive Nhe1
-/-
 mice only a few studies 
have investigated vascular functions in vivo.  
The aim of this thesis was to analyze the role of NHE1 in endothelial cells. To this end, an in vitro 
model was established by downregulating NHE1 in cultured endothelial cells using the RNA 
interference technology. In addition, an endothelial cell-specific Nhe1
-/-
 mouse was generated by 
mating an Nhe1-floxed line with an endothelial cell-specific Cre-recombinase mouse line. Using these 
models together with the constitutive Nhe1
-/-
 mice the following questions were addressed:  
(I) How does NHE1 affect the intracellular pH regulation in endothelial cells as analyzed by live cell 
imaging? 
(II) Does NHE1 influence endothelial proliferation, survival, migration and angiogenesis in vitro? 
(III) Does NHE1 control angiogenesis in vivo as detected in a Matrigel plug assay?  
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2 Methods 
2.1 Materials 
2.1.1 Chemicals 
2-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Germany 
Acetic acid J.T. Baker B.V, Netherlands  
Acrylamide 4K-solution 30 % Mix 29:1 AppliChem GmbH, Germany 
Amersham ECL GE Healthcare UK Limited, UK 
Ammonium chloride Sigma-Aldrich Chemie GmbH, Germany 
Ammonium persulfate AppliChem GmbH, Germany 
AURION BSA-c (Bovine Serum Albumin) Aurion Immuno Gold Reagents & Accessories, 
Netherlands 
BCECF-AM Invitrogen, Molecular Probes, USA 
Bio-Rad DC Protein Assay Bio-Rad Laboratories Inc., Hercules, USA 
Bovine serum albumin Fraction V, pH 7,0 (BSA) AppliChem GmbH, Germany 
Bromphenolblue Sigma-Aldrich Chemie GmbH, Germany 
Calcium chloride AppliChem GmbH, Germany 
Complete, EDTA-free Protease inhibitor cocktail 
tablets (PIC) 
Roche Diagnostic GmbH, Germany 
Disodium hydrogen phosphate dihydrate Carl Roth GmbH & Co. KG, Germany 
DMSO Sigma-Aldrich Chemie GmbH, Germany 
DTT Sigma-Aldrich Chemie GmbH, Germany 
EDTA Sigma-Aldrich Chemie GmbH, Germany 
EGTA Sigma-Aldrich Chemie GmbH, Germany 
Ethanol Carl Roth GmbH & Co. KG, Germany 
Ethidium bromide MERCK, Germany 
Fibrinogen, Human Plasma Calbiochem _R 
FluoromountG Southern Biotech, USA 
Glucose Sigma-Aldrich Chemie GmbH, Germany 
Glucose (GO) Assay Kit Sigma-Aldrich Chemie GmbH, Germany 
Glycerol Carl Roth GmbH & Co. KG, Germany 
Glycin AppliChem GmbH, Germany 
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Goat Serum (Normal) Dako Deutschland GmbH, Germany 
HEPES Sigma-Aldrich Chemie GmbH, Germany 
Human Serum Albumin (HSA) Bayer Vital GmbH, Germany 
Hydrochloric acid 37 %  (HCl) Carl Roth GmbH & Co. KG, Germany 
Isopropanol VEB Jenapharm-Laborchemie, Germany 
Kodak GBX developer and replenisher Sigma-Aldrich Chemie GmbH, Germany 
Kodak GBX fixer and replenisher Sigma-Aldrich Chemie GmbH, Germany 
Lactate Assay Kit Sigma-Aldrich Chemie GmbH, Germany 
Magnesium sulfate Sigma-Aldrich Chemie GmbH, Germany 
Methanol AppliChem GmbH, Darmstadt 
Methylcellulose Sigma-Aldrich Chemie GmbH, Germany 
Sodium diphosphate tetrabasic (Na4P2O7) Sigma-Aldrich Chemie GmbH, Germany 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich Chemie GmbH, Germany 
Nigericin, free acid Invitrogen, Molecular Probes, USA 
N-Methyl-D-Glucamine Sigma-Aldrich Chemie GmbH, Germany 
Paraffin MerckKGaA, Germany 
Paraformaldehyde AppliChem GmbH, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich Chemie GmbH, Germany 
Potassium chloride VEB Jenapharm-Laborchemie, Germany 
Potassium dihydrogen phosphate Riedel-De Haen AG, Germany 
Propidium iodide Sigma-Aldrich Chemie GmbH, Germany 
Saponin E. Merck, Germany 
SeaKem LE Agarose Lonza, USA 
Skimmed milk powder AppliChem GmbH, Germany 
Sodium carbonate MERCK 
Sodium chloride AppliChem GmbH, Germany 
Sodium dodecyl sulfate Sigma-Aldrich Chemie GmbH, Germany 
Sodium hydroxide Carl Roth GmbH & Co. KG, Germany 
Spectra Multicolor Protein Ladder (10-260 kDa) Fermentas GmbH, Germany 
Sulfuric acid Sigma-Aldrich Chemie GmbH, Germany 
TEMED AppliChem GmbH, Darmstadt 
Thrombin, Human plasma Sigma-Aldrich Chemie GmbH, Germany 
Tris(hydroxymethyl)aminomethan (Tris) AppliChem GmbH, Germany 
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tri-Sodium citrate dihydrate Fluka Chemie GmbH, Germany 
Triton X-100 Ferak Berlin GmbH, Germany 
Tween 20  SERVA Electrophoresis GmbH, Germany 
Xylol  VWR (BDH) Prolabo Chemicals, France 
Zinc Fixative IHC  BD Biosciences, San Diego, USA 
2.1.2 General materials 
Biofuge pimo R (centrifuge) Heraeus Holding GmbH, Germany 
BP310P (balance) Sartorius AG, Germany 
BP61 (balance) Sartorius AG, Germany 
Fridge +4 °C / Freezer -20 °C Liebherr-International Deutschland GmbH, Germany 
Hamilton-Syringe Hamilton Bonaduz AG, Switzerland 
Heracell 150 (incubator) Heraeus Holding GmbH, Germany 
Heraeus function line (warming incubator) Heraeus Holding GmbH, Germany 
KH-3 (Cooling system - Blotting) Biometra
®
 Biomedizinische Analytik GmbH, Germany 
KS 501 digital IKA
®
 Werke GmbH 6 Co. KG, Germany 
Labofuge 400R Heraeus Holding GmbH, Germany 
Laminarbox Herasafe Heraeus Holding GmbH, Germany 
M6 Lauda (water bath) MS Laborgeräte, Germany 
Magnet stirrer R3T GmbH, Germany 
MC1 Laboratory LC4200 (scale) Sartorius AG, Germany 
mc6
®
 (fume hood) Waldner Laboreinrichtungen GmbH & Co. KG 
Medap (vacuum vessel)  
Medizinische Apparate, Med.-Techn. Gasanlagenbau, 
Austria 
2.1.3 General instruments 
Biofuge pimo R (centrifuge) Heraeus Holding GmbH, Germany 
BP310P (balance) Sartorius AG, Germany 
BP61 (balance) Sartorius AG, Germany 
Fridge +4 °C / Freezer -20 °C 
Liebherr-International Deutschland GmbH, 
Germany 
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Hamilton-Syringe Hamilton Bonaduz AG, Switzerland 
Heracell 150 (incubator) Heraeus Holding GmbH, Germany 
Heraeus function line (warming incubator) Heraeus Holding GmbH, Germany 
KH-3 (Cooling system - Blotting) 
Biometra
®
 Biomedizinische Analytik GmbH, 
Germany 
KS 501 digital IKA
®
 Werke GmbH 6 Co. KG, Germany 
Labofuge 400R Heraeus Holding GmbH, Germany 
Laminarbox Herasafe Heraeus Holding GmbH, Germany 
M6 Lauda (water bath) MS Laborgeräte, Germany 
Magnet stirrer R3T GmbH, Germany 
MC1 Laboratory LC4200 (scale) Sartorius AG, Germany 
mc6
®
 (fume hood) Waldner Laboreinrichtungen GmbH & Co. KG 
Medap (vacuum vessel)  
Medizinische Apparate, Med.-Techn. 
Gasanlagenbau, Austria 
Microprocessor pH meter ph537 
WTW Wissenschaftlich-Technische Werkstätten 
GmbH, Germany 
Microwave Sharp Electronics GmbH, Germany 
MP20/System II (membrane vacuum pump) 
Biometra® Biomedizinische Analytik GmbH, 
Germany 
OV3 (warming incubator) 
Biometra® Biomedizinische Analytik GmbH, 
Germany 
Pharmacia LKB MultiTemp II (cooling system - 
electrophoresis) GE Healthcare UK Limited, UK 
Power Pac 1000 (electrophoresis) Bio-Rad Laboratories Inc., USA 
Power Pac 200 (blotting) Bio-Rad Laboratories Inc., USA 
Präzitherm Typ PZ 35  Störk-Tronic, Störk GmbH & Co. KG, Germany 
Protean® II xi Cell (electrophoresis) Bio-Rad Laboratories Inc., USA 
Shaker Eppendorf AG, Germany 
Thermomixer 5437 Eppendorf AG, Germany 
Thermostat Julabo JULABO Labortechnik GmbH, Germany 
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Trans-Blot™ Cell (blotting) Bio-Rad Laboratories Inc., USA 
Vortex IKA® Werke GmbH 6 Co. KG, Germany 
WT17 (tumbling shaker) 
Biometra® Biomedizinische Analytik GmbH, 
Germany 
centrifuge 5415 C Eppendorf AG, Germany 
2.1.4 Cell culture 
BioWhittkaer® human serum Lonza, Walkersville Inc., USA 
BioWhittkaer® medium 199 (M199) Lonza, Ealkersville Inc., USA 
Ciprofloxacin Kabi Fresenius Kabi Deutschland GmbH, Germany 
Collagenase II Worthington Biochemicals Corporation, USA 
Dulbecco`s modified Eagle`s medium 
(DMEM/F12 1X) 
Gibco® Life Technologies Corporation, UK 
Dulcecco’s modified Eagle medium (high 
glucose)) 
PPA Laboratories GmbH,  
Endothelial mitogen (EM) Biomedical Technologies Inc., USA 
Fetal calf serum (FCS) Cambrex Bio Science Verviers SPRL, Belgium 
Gelatine ICN Biomedicals GmbH, Germany 
Hank`s balanced salt solution (HBSS) Cambrex Bio Science Verviers SPRL, Belgium 
Heparin-sodium  Hoffmann-La Roche AG,  
L-Glutamine ICN Biomedicals GmbH, Germany 
Penicillin/streptomycin  Cambrex Bio Science Verviers SPRL, Belgium 
Saint-Red siRNA/RNAi-delivery system  Synvolux Therapeutic B.V., Belgium 
Trypsin-EDTA (0,05 % / 0,02 %) Sigma-Aldrich Chemie GmbH, Germany 
Trypsin inhibitor Sigma-Aldrich Chemie GmbH, Germany 
Vitamin C 
 
Sigmal-Aldrich Chemie GmbH, Germany 
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2.2 Endothelial cells used for in vitro experiments 
In vitro experiments were done with primary human umbilical vein endothelial cells (HUVEC) 
prepared from human umbilical cords, and primary mouse lung endothelial cells (MLEC) derived 
from the mouse lungs. 
2.2.1 Preparation of human umbilical vein endothelial cells (HUVEC) 
The fresh cords were cleaned with 70% ethanol from the outside. The vein was perfused with sterile 
washing buffer (see Table 1 for media and buffers composition), and then filled and incubated with 
0.01% Collagenase II in M199 for 3 min at 37 
°
C. Dissociated cells were then collected in a tube with 
stop medium and centrifuged for 6 min at 500 g. The cells were resuspended in stop medium and 
seeded in a 0.2% gelatine pre-coated 75 cm
2
 cell culture flask and incubated at 37 
°
C, 5% CO2 and 
95% humidity overnight. Afterward, the cells were washed with PBS to remove non-adherend cells, 
and fresh growth medium was added (supplemented with 0.5% Ciprofloxacin until the first passage). 
After reaching confluency, the cells were washed with PBS, detached with trypsin-EDTA 
(0.05%/0.02%) and propagated into new flasks. Each batch of HUVEC was cultured and employed up 
to a maximum of three passages. Each biological repetition was done with HUVEC obtained from 
independent preparations. 
Washing buffer (for the umbilical vein) 
NaCl                               0.9% 
Penicillin 100 U/ml 
Streptomycin 100 µg/ml 
 
Stop medium 
FCS 10% 
Penicillin 100 U/ml 
Streptomycin 100 µg/ml 
 in M199 
 
PBS (phosphate buffered saline) 
NaCl 145 mM 
KCl 2.7 mM 
KH2PO4 1.5 mM 
Na2HPO4 8 mM 
pH adjusted to 7.4, autoclaved and stored at 4 
°
C 
 
Table 1: Media and buffers used for HUVEC preparation 
200 mM Vitamin C (stock) 
Freshly prepared in M199 and neutralized 
with 0.2 M NaOH 1:5 (V/V)  
 
Gelatine 
0.2% gelatine was dissolved in ddH2O at  
56 
°
C and sterile-filtered and stored at 4 
°
C 
Growth medium 
FCS 17.5% 
Human serum 2.5% 
Penicillin 100 U/ml 
Streptomycin 100 µg/ml 
L-Glutamine 680 µM 
Heparin 25 µg/ml 
Endothelial mitogen 7.5 µg/ml 
Vitamin C 5 µg/ml 
 in M199 
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2.2.2 Preparation of mouse lung endothelial cells (MLEC) 
Lung endothelial cells were prepared from animals of different genotypes (see section 2.9.1). 
Constitutive Nhe1
-/-
 were employed at age of 3 weeks, since they die early in life; wild type littermates 
of the same age were used as controls. Endothelial cell-specific Nhe1
-/-
 mice were processed at the age 
of two months; mice of Nhe1
flox/flox
 genotype without Cre-recombinase were used as controls. All 
animals were sacrificed by cervical dislocation and the skin was disinfected with 70% ethanol. The 
lungs were excised and washed in ice-cold DMEM. The tissue was minced and incubated in 0.2% 
Collagenase II in DMEM for 1 h at 37 
°
C under gentle mixing every 10 min. The digest was triturated 
20-30 times with blunt edge cannula and filtered through a 40 µm cell strainer to remove undigested 
tissue. (-) Medium (see Table 2 for media composition) was used to wash the strainer and stop the 
enzymatic activity, and the suspension was centrifuged at 500 g for 10 min. The cells were 
resuspended in (+) medium and seeded in 75 cm
2
 culture flasks pre-coated with 0.2% gelatine. On the 
next day, the mixed culture of lung tissue-derived cells was briefly washed with 2% FCS in PBS and 
was incubated further in (+) medium. The first positive enrichment for endothelial cells was performed 
before full confluence of the culture was reached (to prevent non-endothelial cell overgrowth). To this 
end, magnetic beads coupled to secondary antibody (3 x 10
6
 beads per 75 cm
2
 flask) (Table 2) were 
washed with 2 % FCS in PBS and then conjugated with anti-CD102 antibody (4.5 µg per 75 cm
2
 
flask) for 2 h at 4 
°
C under slight tumbling. Beads were washed with the help of a magnet (Dynabeads 
MPC-S; Dynal Biotech ASA). Mixed cell cultures were then incubated with the anti-CD102-
conjugated beads for 1 h at 4 
°
C. Thereafter, culture was trypsinized and transferred into a 15 ml tube, 
which was filled up to the maximal volume with (-). A second 15 ml tube was placed in the magnet 
and the cell suspension was pipetted over 4-6 min at the side where the tube contacts the magnet. 
Thereby, endothelial cells with beads were allowed to stay at the tube wall, whereas other cell types 
remained suspended. After 10 min incubation - allowing all cells with beads to be dragged by the 
magnet to the tube wall - the medium containing bead-free cells was poured out and the tube was 
removed from the magnet. Bead-binding cells were detached from the wall with (+) medium and 
seeded in new culture flasks. Selection was repeated once after confluence was reached again (to 
increase culture purity) and cells were seeded for experiments. Medium was changed daily to provide 
optimal growth conditions yielding 5-10 x 10
6
 MLEC per mouse. Culture purity was checked for each 
preparation by flow cytometry staining CD31 as an endothelial marker (see section 2.10.2.1). It 
fluctuated between 80–95 %. 
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Table 2: Antibodies and media used for MLEC 
preparation 
Antigen Type (IgG) Cat No Vendor 
Anti-Mouse-
CD102 
rat anti-
Mouse 
553326 BD 
Biosciences 
Dynabeads sheep anti 
Rat 
110.35 Dynal Biotech 
ASA 
 
 
2.3 Transfection of HUVEC with siRNA 
HUVEC were transfected at 50-60% confluency with siRNAs directed against NHE1, HIF1α or 
HIF2α (Table 3). The Saint-Red siRNA/RNAi-Delivery System (Synvolux Therapeutics B.B.) was 
used for lipofection. Prior to transfection, the cells were washed twice with pre-warmed Hank’s 
balance salt solution (Cambrex Bio Science Verviers SPRL), and incubated with Saint-Red (15 
nmol/ml) and siRNA (0.5 µg/ml or 37 nM) in serum-free medium (0.25% HSA in M199). Growth 
medium was added four hours later, and the culture was usually used for experiments within 120 h 
after transfection. In parallel, cells transfected with non-targeting siRNA were used as controls. 
Downregulation efficiency was verified by western blotting, immunocytochemistry or flow cytometry. 
Table 3: siRNAs used for experiments with protein downregulation 
Target mRNA Design Cat No 
Non-targeting 
(control) 
Dharmacon On-Targetplus siCONTROL Non-targeting Pool D-001810-10 
HIF1α SMARTpool: ON-TARGETplus HIF1A siRNA L-004018-00 
HIF2α (EPAS1) SMARTpool: ON-TARGETplus EPAS1 siRNA L-004814-00 
NHE1 Dharmacon siGENOME SMARTpool Human SLC9A1 M-005277-00 
All siRNAs were purchased from GE Healthcare, Dharmacon RNAi & Gene Expression. 
2.4 Cell stimulation 
For short-term stimulation of up to 30 min, the cells were starved for four hours in serum-free medium 
(M199 containing 0.25% HSA). 30 min before stimulation with VEGF (Cat. nr.: 296-VE, R&D 
Systems) and S1P (Cat. Nr. 567727, Calbiochem), medium was substituted with HEPES-buffered 
solution containing 0.25% HSA and cells were incubated at 37 
°
C without CO2. Stimuli were added to 
this medium. 
(-) Medium 
FCS 20% 
Penicillin 100 U/ml 
Streptomycin 100 µg/ml 
L-Glutamine           2 mM 
 in DMEM/F12 
(+) Medium 
Heparin 25 µg/ml 
EM 75 µg/ml 
 in (-) medium 
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For long-term stimulation of 24 to 48 h, the cells were starved in low serum medium (Table 4) for four 
hours, to which VEGF or 1P was then added. 
2.5 Cell proliferation and survival 
The cells were transfected with control or NHE1 siRNA. 48 h after transfection, proliferation was 
either analyzed in growth medium or cells were first reseeded on 35 mm dishes at 1.5 x 10
4
 cells/cm
2
 
for VEGF-induced proliferation experiments. For the second case, the cells were stimulated with 50 
ng/ml VEGF the following day after reseeding and counted 24 and 48 h after stimulation. One sample 
per each siRNA was analyzed at the time of stimulation and denoted as “0 h”. In addition to cell 
counting, cell cycle (see section 2.10.2.2) and viability (see section 2.10.2.2 and 2.10.2.3) were also 
analyzed. 
2.6 Hypoxia 
The cells were incubated for up to 72h under hypoxic conditions with 1% O2, 5% CO2 and 95% 
humidity at 37 
°
C (HERAcell 150i; Thermo Fischer Scientific) for up to 72 h. Medium was first 
equilibrated in hypoxic conditions before medium changes took place. 
2.7 Protein preparation for western blot analysis  
The cells were washed with ice-cold wash-lysis buffer and were incubated with lysis buffer on ice for 
15 min. The cells were then scraped off the plastic surface and the collected cell lysates were 
centrifuged (700 g, 6 min, 4 
°
C), and the supernatant was transferred into a new tube. After taking 
aliquots for determination of protein concentration, 3x Laemmli buffer was added to the lysate and 
proteins were denaturized for 5 min at 95 
°
C under gentle shaking. The lysates were stored at -20 
°
C. 
Protein concentration was determined using the Lowry method and analyzed spectrophotometrically 
(Uvikon 930; Tresser Instruments). 
Low serum medium 
FCS 2% 
Penicillin 100 U/ml 
Streptomycin 100 µg/ml 
L-Glutamine           2 mM 
Heparin 25 µg/ml 
Vitamin C 5 µg/ml 
 in M199 
 
HEPES-buffered solution 
NaCl 145 mM 
KCl   5 mM 
CaCl2 1.5 mM 
MgSO4 1 mM 
HEPES (buffer substance) 10 mM 
Glucose 
 
10 mM 
pH adjusted to 7.4, sterile filtered  
and stored at 4
 °
C 
Supplemented with 0.25% HSA before use 
 
Table 4: Low serum medium and HEPES-buffered solution used for stimulation experiments 
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For immunoblotting, 30-50 μg protein per lane were separated through a water-cooled and electrode 
buffer-filled 7.5% SDS-PAGE. The separated proteins were transferred onto polyvinylidene fluoride 
membranes using a water-cooled and blotting buffer-filled wet blotting technique. The protein-loaded 
membranes were then blocked with 5% non-fat dry milk in TN-tween buffer for 1 h at RT, followed 
by an overnight incubation with primary antibodies (see Table 2 for antibodies) at 4 
°
C. Membranes 
were washed and incubated with peroxidase-coupled secondary antibody for 1 h at RT. After another 
washing step, the peroxidase-coupled secondary antibodies were visualized with an enhanced 
chemiluminescence Kit on autoradiography films. Before probing with another primary antibody, the 
membranes were treated with stripping buffer for 35 min at 54 
°
C under gentle shaking to remove the 
previously bound primary antibody. Between each step, the membranes were washed with TN-Tween 
buffer, while the last wash before chemiluminescence detection was done with TN-buffer without 
tween. Finally, the films were scanned, and the protein bands were quantified with the ImageJ 
software (National Institutes of Health). 
 
Wash-lysis buffer 
Tris pH 7.4 50 mM 
EDTA 2 mM 
EGTA       1 mM 
NaF 50 mM 
 stored at 4 
°
C 
freshly added:  
Na4P2O7 100 mM 
Na3VO4 1 mM 
DTT 1 mM 
 
Lysis buffer 
Triton X-100 1% 
SDS 0.1% 
PMSF       0.2 M 
PIC 10 µl/ml 
           added freshly to Wash-lysis buffer 
Electrode buffer 
Tris 192 mM 
Glycine 25 mM 
SDS          0.1% 
 pH 8.3; stored at RT 
 
Blotting buffer 
Tris 25 mM 
Glycine 192 mM 
SDS          0.1% 
 stored at 4 
°
C, + 10% methanol added freshly 
 
3x Laemmli buffer 
SDS 9% 
Glycerol 15% 
Tris pH 6.8 186 mM 
EDTA                                              10 mM 
2-Mercaptoethanol 6% 
Bromphenolblue 0.03% 
 stored at -20 
°
C 
 
TN-buffer 
NaCl                                                0.15 M 
Tris                                                    1 mM 
 stored at 4 
°
C 
 
 
TN-Tween buffer 
Tween 20 in TN-buffer 0.1% 
 
Protein standard (westernbloting) 
BSA                                                           10 mg 
in 10 ml 0.9 % NaCl solution, stored at 4 °C 
 
 
Stripping buffer 
Tris 62.5 mM 
SDS 2% 
pH 6.7, stored at RT, before use warmed to 54 
°
C 
and supplemented with 100 mM 
2-mercaptoethanol 
 
Table 5: Buffers and solutions used for protein preparation, SDS-PAGE and western blot analysis 
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Table 6: Antibodies used in western blot analysis 
Primary antibodies were dissolved in 5% BSA in TN-tween buffer (supplemented with 0.02% sodium azide) and 
stored at 4 
°
C. Secondary antibodies were dissolved in 5% milk in TN-tween buffer. Antibodies were purchased 
from Cell Signaling Technology (USA); or * EMD Millipore (USA), 
#
 BD Biosciences (USA), 
$
 Kirkegaard & 
Perry Laboratories (USA), 
§ 
Novus Biological (USA). 
 
Antigen Phosphorylation site Type (IgG) Dilution Cat No  
β-Actin  rabbit, monoclonal 1:5 000 4970 
eNOS  mouse, polyclonal 1:2 000 610297
#
 
HIF1α  rabbit, polyclonal 1:1 000 3716 
HIF2α  rabbit, polyclonal 1:1 000 NB100-122§ 
NHE1  mouse, monoclonal 1:1 000 mab3140* 
p44/42 MAPK  mouse, monoclonal 1:2 000 9107 
panAkt   rabbit, monoclonal 1:1 000 4691 
panAMPK  rabbit, polyclonal 1:1 000 2532 
Phospho-Akt Ser473 rabbit, polyclonal 1:1 000 9271S 
Phospho-AMPK Thr172 rabbit, monoclonal 1:1 000 2535 
Phospho-eNOS 
TypIII S1177 rabbit, monoclonal 1:1 000 9570S 
Phospho-p42/44 
MAPK T202/204 mouse, monoclonal 1:5 000 9106 
Phospho-VEGFR2 Y1175 rabbit, monoclonal 1:1 000 2478 
Phspho-Akt Thr308 rabbit, monoclonal 1:1 000 4056 
Vinculin  rabbit, monoclonal 1:5 000 4650 
Mouse IgG (H+L) 
  
goat polyclonal, 
peroxidase labeled 
1:5 000 
 
074-1806
$ 
 
Rabbit IgG (H+L) 
  
goat polyclonal, 
peroxidase labeled 
1:5 000 
 
074-1506
$ 
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2.8 Assays to evaluate endothelial function in vitro 
2.8.1 Spheroid assay 
Groups of endothelial cells can be also grown as spheres. When embedded in a 3D fibrin gel and 
stimulated with angiogenic factors, the spheres produce sprouts representing capillary-like structures. 
This assay is used to study in vitro angiogenesis by quantifying sprout number and length (see Figure 
2-1).  
 
Figure 2-1: Sprouting of spheroids and analysis 
Spheroids embedded in 3D fibrin gel (A) sprout with capillary-like structures when stimulated with an 
angiogenic factor like VEGF (B). The sprout number and average length are analyzed to quantify in 
vitro angiogenesis. 
To generate spheroids, trypsinized HUVEC were set to 37,500 cells/ml in growth medium. This cell 
suspension was mixed with methylcellulose (12 mg/ml) in a 5:1 volume ratio, of which 3,000 
cells/well (100 µl) were seeded in round bottom 96-well plates and incubated overnight at 37 
°
C. The 
formed spheroids were pooled in tubes and washed twice with HEPES-buffered solution (centrifuged 
in between for 4 min at 200 g). Fibrinogen dissolved in HEPES-buffered solution was sterile-filtered 
and diluted with the spheroid suspension to a final concentration of 1.8 mg/ml. The mixture was 
supplemented with 200 U/ml aprotinin to block the degradation of the fibrin gel. 300 µl per well of 
this suspension were polymerized with 10 µl thrombin (final concentration of 0.66 U/ml) in 24-well-
plates for 20 min at 37 
°
C (without CO2). Low serum medium was then added and changed three times 
in 10 min intervals to wash away the thrombin. Finally, the embedded spheroids were incubated in low 
serum medium (without or with VEGF: 10 ng/ml or 50 ng/ml) for 48 h. Afterward, spheroids were 
fixed with 4% PFA for 10 min at RT and washed with PBS. Each experiment included technical 
duplicates (two wells per condition) and approximately 10 spheroids per well were documented (Axio 
Vert 200; Zeiss) and analyzed with CellD software (Olympus) for sprout number and length. 
Preparation of methylcellulose solution: Methylcellulose was autoclaved as powder and then stirred in 
M199 medium (24 g/l) for 20 min at 60 
°
C. This solution was further diluted with M199 to 12 g/l and 
Unstimulated VEGF Analyzed 
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stirred for one hour at RT and then overnight at 4 
°
C. The resulting solution was centrifuged for two 
hours at 4000 g, and the supernatant was collected for the experiments. 
2.8.2 Transwell migration assay 
The transwell assay estimates cell migration through 0.8 µm pores on membrane inserts (FALCON
®
 
Transwell insert; Corning Incorporated). Cells were seeded on the upper side and migrate towards the 
chemoattractant in the lower chamber on the other side of the membrane (Figure 2-2). The cells were 
starved for three hours in serum-free medium and were then trypsinized. Instead of stop medium, a 
Trypsin-inhibitor (1 mg/ml; Sigma-Aldrich) was used to stop Trypsin’s activity and prevent FCS-
stimulation. The detached cells were centrifuged for 6 min at 500 g and resuspended in M199 
containing 0.25% HSA. Inserts were placed on 24-well-plates and coated with 0.2% gelatine. 
Immediately after aspirating the gelatine 8 x 10
4
 cells were seeded on the upper chamber of each 
insert. The lower chamber was filled with serum-free medium and supplemented with 50 ng/ml VEGF 
or 0.1 µM S1P to stimulate migration, whereas no attractants were added to controls. Cells were 
allowed to migrate for four hours and fixed with 4% PFA in PBS for 10 min at RT. Next, inserts were 
washed with distilled water four times for 2.5 min each and stained with hematoxylin for 5 min. 
Membranes were then washed thoroughly with tap water and left for 10 min in tap water for the color 
to develop. Non-migrated cells on the upper side of the membrane were removed with a cotton swab 
and membranes were air dried at RT overnight. Membranes were excised from the inserts with a 
crooked scalpel and embedded with FluoromountG on microscope slides. Each experiment included 
technical duplicates and five pictures per insert were taken at a 200x magnification. Migrated cells 
were counted manually with ImageJ software.  
 
Figure 2-2: Transwell migration assay 
Cells were seeded on the upper chamber of the insert while the stimulant was pipetted on the lower chamber. 
After 4 h migrated cells were positioned on the lower side of the membrane (A). The inserts were fixed and 
stained (B), and the non-migrated cells on the upper part were removed with a cotton swab (C). The inserts were 
placed on microscopic slides and imaged at five different positions before analysis (D). 
2.8.3 2D Chemotaxis 
IbiTreat chemotaxis µ-Slides [95] (µ-Slides Chemotaxis
3D
; ibidi GmbH) were used to study HUVEC’s 
ability to sense chemotactic gradients in vitro in (Figure 2-3). Slides were handled according to the 
manufacturer´s instructions to study 2D chemotaxis of adherent cells. The HUVEC were trypsinized 
72 h after transfection with control or NHE1 siRNA and seeded on the chemotaxis slides at a low 
A B C D 
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confluency, although a high density suspension of 2-3 x 10
6
 cells/ml was needed due to the small 
height of the observation area. Although cells  beca Three hours later, the cells were carefully washed 
three times and incubated further in low serum medium, which was pre-incubated in 5% CO2 air for 
pH equilibration. Three hours later, 50 ng/ml VEGF or 0.1 µM S1P was added to the right chamber, 
whereas controls were left unstimulated. Slides were immediately placed on the motorized stage of the 
microscope (Nikon Eclipse Ti) in a chamber warmed at 37 
°
C and flooded with 5% CO2 humidified 
air. A larger area was scanned in 10 min intervals under 200x magnification by automatically stitching 
4 x 7 individual images. The Nikon Perfect focus system was used to keep cells in focus. The 
experiment was stopped after 24 h and migrating cells (cell nuclei) were tracked in ImageJ software 
using the Manual Tracking plugin. The tables obtained from ImageJ software were analyzed with 
Chemotaxis and Migration Tool software. Among the parameters analyzed (Figure 2-3), the 
displacement of the Center of Mass (COM), Forward Migration Index (FMI), and the migration 
velocity were chosen to describe migrational behaviour of the cells. These parameters were calculated 
for the parallel axis of the gradient and the perpendicular axis. Theoretically, no net displacement of 
COM should be observed in the perpendicular axis. 
2.8.4 Wound healing 
The wound healing assay was used as another approach to study HUVEC migration after NHE1 
knockdown. Instead of scratching a confluent cell monolayer, which is usually inhomogenous, a 
uniform cell free area of approximately 500 µm wide, in which endothelial cells could move in, was 
created using ibidi Culture inserts in 35 mm µ-Dishes (ibiTreat) as shown in Figure 2-4. The inserts 
were handeled according to the manufacturer´s manual. HUVEC were trypsinized and seeded on the 
inserts (4 x 10
4
 cells/well) 72 h after transfection . The inserts were removed 3-4 h after seeding, in 
order to avoid the detachment of the cell monolayer together with the insert. The cells were washed, 
and low serum medium was added, which was pre-incubated in 5% CO2 air for pH equilibration. Two 
to three hours later 50 ng/ml VEGF or 0.1 µM S1P was added, whereas controls were left 
unstimulated.  
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Figure 2-3: Chemotaxis assay 
Panel A shows from above the space of the slide in which the cells are seeded and where the gradient forms. In 
this panel some cell tracking’s are also shown as the majority of cells move towards the stimulant on the right. 
Panel B shows the slide in perpendicular section with two medium pools and the narrow slit where cells are 
attached and the gradient forms. Panel C shows the analysis of cell trackings with some of the parameters that 
can be analyzed. 
 
 
Following the stimulation, the dishes were immediately placed on the motorized stage of the 
microscope (Nikon Eclipse Ti) in a chamber warmed at 37 
°
C and flooded with 5% CO2 humidified 
air. A larger area was scanned in 10 min intervals at 200x magnification by automatically stitching 11 
x 4 individual images, while the Nikon Perfect focus system was used to keep the cells in focus over 
24 h. Cell nuclei within the wound area were counted with ImageJ software in two hours intervals for 
six hours, at which point the opposite sides of the wound usually reached each other. 
A B 
C 
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Figure 2-4: Wound healing assay 
After attaching the culture inserts to the dish bottom (A), cells were seeded in the insert’s wells (B) 
and 3 h later the insert was removed (C) leaving an empty area between the two monolayers. The dish 
was filled with low serum medium (D) to which stimulants were added after 2 h of starvation. Cells 
migration into the wound was tracked within the first 6 h after stimulation (E). 
2.9 Molecular biology 
2.9.1 Mouse lines 
Nhe1-floxed: Exon 2 coding for 4 out of 12 transmembrane domains of NHE1 was flanked by loxP 
sites as shown in Figure 2-5. After Cre-lox recombination, loss of exon 2 leads to a frameshift and a 
premature stop codon that results in a destabilized mRNA. The Nhe1-floxed line was backcrossed with 
C57BL/6 and used to generate both the constitutive (ubiquitous Cre deleter [96]) and the endothelial 
cell-specific Nhe1
-/-
 mice (VE-Cadherin-Cre [97]). The Nhe1-floxed mouse line was generated by Dr. 
Christopher Hennings. 
Mouse line Modification Reference 
Nhe1-flox conditional construct Generated by 
Dr. Christopher Hennings 
VE-Cadherin-Cre  
(Cdh5-cre) 
transgene [97] 
Tie2-cre transgene [98] 
Tomato 
ROSA-locus 
knockin [99] 
Cre-Rekombinase 
Ubiquitous deleter 
transgene [96] 
Table 7: Mouse lines 
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Figure 2-5: The strategy for the conditional knockout of the Nhe1 allele 
Exon 2 of the Nhe1 allele is flanked by two loxP sites (A) and cre-recombination results in gene knockout since 
the loss of exon 2 leads to a frameshift and a premature stop codon (D). The binding stie for genotyping primers 
are also depicted (A, D) as well as the resulting amplicons (B, C). 
 
2.9.2 Phenol/chloroform extraction of genomic DNA 
In order to extract genomic DNA, tail biopsies (2-3 mm) were incubated overnight at 55 
°
C in 500 µl 
lysis buffer (50 mM Tris 100 mM EDTA, 100 mM NaCl, 1% SDS, pH 8.0) supplemented with 10 µl 
Proteinase K (14 mg/ml). After cooling, one volume of TE-buffered phenol-chloroform-isoamyl 
alcohol (25:24:1, Roth) was added, and the lysates were mixed on a rotator for at least 5 min at RT. 
The samples were then centrifuged at maximal speed over 10,000 g for 15 min at 4 
°
C, and the upper 
aqueous phase was collected in new tubes. Traces of phenol were removed through two consecutive 
washes with one volume chloroform-isoamyl alcohol (24:1), and DNA was precipitated with one 
volume isopropanol (supplemented with 8 mM LiCl). The DNA pellet was washed once with 70% 
ethanol and air-dried. The pellet was then solubilized in 150 µl low TE buffer (10 mM Tris, 1 mM 
EDTA, pH 7.4) overnight at 55 
°
C, and stored at 4 
°
C or -20 
°
C for further use. 1-2 µl were used in the 
PCR for genotyping. 
2.9.3 HotSHOT DNA extraction 
In a faster alternative for genomic DNA extraction, tail-biopsies (2-3 mm) were incubated in 75 µl 
alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA, pH 12.0  – no adjustment) for 30-60 min at 95 
°
C, cooled on ice and neutralized with acidic buffer (40 mM Tris-HCl, pH 5.0–no adjustment). 
Extracted DNA was stored at 4 
°
C or -20 
°
C. 1-2 µl were used for the PCR reaction for genotyping. 
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2.9.4 Genotyping 
DNA prepared by HotSHOT or Phenol/Chloroform extraction was used for genotyping in a 
polymerase chain reaction (PCR) using Taq-Polymerase (Invitrogen).  The PCR products were 
separated by horizontal gel electrophoresis (2% agarose in running buffer: 40 mM Tris-Acetate, 1 mM 
EDTA) and visualized by supplementing the gel with 0.5 µg/ml ethidium bromide. Samples were 
mixed with 5x DNA loading buffer (30% Glycerin, 0.25% bromophenol blue and 0.25% xylene 
cyanol), and the fragment sizes were compared to a 1 kb DNA ladder (Gene graft). Amplicons were 
separated at a constant voltage of 160 V for 30-90 min and visualized under ultraviolet light. 
For Nhe1-flox genotyping, the PCR was set with three primers to amplify the Nhe1-wildtype (451 bp), 
Nhe1-floxed (495 bp), and Nhe1-knockout allele (525 bp) (see Figure 2-5 for the genotyping strategy 
and Table 8 for primer sequences). 
Table 8 Nhe1 genotyping primers 
Nhe1 Primers sequence (5´-3´) 
Nhe1_for TTA GGA GCT GGG AAG GAG AGT 
Nhe1_revI/MP CTT CTT GTG CTG AAA AGC TGC C 
Nhe1_KO GCA TTC ACA CCT GAA CTA AGC 
2.9.5 Quantitative real-time PCR angiogenesis array 
To find a link between NHE1 and VEGF-stimulated angiogenesis, we have analyzed the expression of 
84 angiogenesis-related genes with the Qiagen qPCR angiogenesis array (RT
2
 Profiler™ PCR Array 
Human Angiogenesis). For this experiment, HUVEC were seeded in 90 mm cell culture dishes and 
were transfected the next day. 72 h after transfection, the cells were starved for four hours in low 
serum medium and stimulated with 50 ng/ml VEGF for 4 or 24 h with appropriate unstimulated 
controls. 
The time-points for stimulation were chosen after a careful review of the literature for the VEGF-
induced expression kinetics of the array-covered genes. The majority of genes were analyzed at 24 h 
after VEGF stimulation, whereas the remaining genes were analyzed after four hours including 
ANGPTL4, CCL11, CXCL10, CXCL9, EDN1, F3, FGFR3, FTL1, IFNA1, IL1B, IL6, IL8, MMP2, 
MMP9, MMP14, NOS3, PTGS1, S1PR1, SERPINE1, SERPINF1 and TIE1. We have used Qiagen 
kits for each step of sample preparation and analysis. RNA was isolated with the RNeasy Kit, from 
which cDNA was synthesized using the RT
2
 First Strand Kit. The obtained Ct values from the qPCRs 
were analyzed using a Qiagen Web-based software. Genes with at least twofold difference were 
considered further. 
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2.10 Analysis using fluorescent probes 
2.10.1 Live cell imaging for intracellular pH measurements 
Intracellular pH (pHi) in living cells was measured using 2′,7′-Bis(2-carboxyethyl)-5(6)-
carboxyfluorescein (BCECF) [100] as a ratiometric fluorescent indicator, it is pH-sensitive when 
excited with a wavelength of 495 nm and pH insensitive at 440 nm (its isosbestic point). This allows 
monitoring pHi independently of dye loading or leakage from the cell, as well as photobleaching 
[101]. The esterified form BCECF-AM is permeable through the cell membrane and trapped inside the 
cell after cleavage by intracellular esterases. For these experiments 18 mm-diameter glass coverslips 
were used, which were pretreated with 1% SDS, 3 x washed for 10 min with distilled water, incubated 
for 10 min with 70% ethanol and 30 min with 99% ethanol, and finally heat sterilized. Thereafter, 
coverslips were coated with 0.2% gelatine before HUVEC or MLEC were seeded on them and loaded 
with 4 µM BCECF-AM in HEPES-buffered solution for 10-15 min at 37 
°
C. Coverslips were mounted 
in a perfusion chamber (Chamlide EC; Live Cell Instruments, Korea) with a heated stage (37 
°
C). The 
cells were then superfused with 37 
°
C warmed HEPES-buffered solution at a linear flow rate of 1.5-2.0 
ml/s (Peri-Star Pro; World Precision Instruments, USA), which corresponds to approximately four 
complete buffer changes per minute. Emitted light of 510-535 nm was recorded after alternating 
excitation at 495 nm and 440 nm and captured through a 10x objective in 30 seconds intervals (to 
reduce phototoxic effects) or 5 seconds when quick changes were expected with a charge-coupled 
device camera (AxioCam MRm; Zeiss) on Axio Observer.Z1 microscope (Zeiss). Steady-state pHi 
was recorded for at least 10 min before the cells were acid-loaded by the “rebound acidification” 
technique [102] for 5 min with 10 mM ammonium chloride in HEPES-buffered solution (equimolar 
substitution of NH4
+
 for Na
+
). The cells were then washed with Na
+
-free HEPES-buffered solution 
(equimolar substitution of N-Methyl-D-glucamine for NaCl) for 5 min. Experiments were also done in 
the presence of bicarbonate in which case solutions were buffered with HCO3
-
/CO2 instead of HEPES. 
Upon reintroduction of Na
+
, pHi recovery was observed, and δpHi/dt was determined for the first 40 
seconds of recovery. Data from more than three coverslips (>30 cells/coverslip) from at least three 
independent preparations were averaged. At the end of each experiment, a calibration curve was 
constructed with a calibration buffer of pH ranging from 6.6-7.4 and supplemented with nigericin as 
an ionophore. A linear regression was calculated from the multipoint calibration curve, and F495/F440 
ratio was converted into pHi values [101].   
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2.10.2 Flow cytometry 
1-5 x 10
4
 cells per sample were measured using the BD FACS Canto flow cytometer (BD Biosciences, 
USA) and analyzed with the FlowJo software. Unstained and single stained controls were used to 
compensate for spectral overlap in multicolor assays. 
2.10.2.1 Analysis of MLEC purity 
The efficiency of positive enrichment for mouse lung endothelial cells (MLEC) was determined using 
flow cytometry. The cell culture was washed with warm PBS and fixed with 0.5% PFA for 2-3 min on 
ice. The mild fixation protocol maintains the CD31 antigen recognizable and allows trypsinization 
after which cells are processed in suspension. The cells were washed twice with PBS (centrifuged in 
between for 6 min at 500 g) and blocked with 0.2% BSA-c in PBS for 30 min at RT. The anti-CD31 
antibody was added to the suspension and incubated for further 30 min. After washing with PBS, the 
cells were incubated for 30 min with secondary antibody (diluted in 0.2% BSA-c in PBS). Finally, the 
cells were washed once and re-suspended in PBS to be analyzed by flow cytometry.  
2.10.2.2 Cell cycle analysis with propidium iodide 
This method quantifies cell DNA and estimates the fraction of cells in each phase of the proliferation 
cycle (G0/G1; S; G2/M). G0 and G1 or G2 and M phase cells contain the same amount of DNA and are 
therefore indistinguishable. Additionally, cells undergoing apoptosis release apoptotic bodies with less 
DNA than the intact cell and constitute the sub-G1 population. Cell clumps were excluded from 
analysis after plotting the height against the width of the signal for propidium iodide fluorescence. 
The supernatant was pooled together with the washing fractions and the trypsinized cell suspension. 
The cells were washed twice with PBS (centrifuged in between for 6 min at 500 g). After resuspension 
in 200 µl PBS, 2 ml of 70% ethanol were added dropwise, and fixation in ethanol was done at 4 
°
C for 
HEPES-buffered solution 
NaCl 145 mM 
KCl   5 mM 
CaCl2 1.5 mM 
MgSO4 1 mM 
HEPES (buffer substance) 10 mM 
Glucose 10 mM 
    pH adjusted to 7.4, sterile filtered 
stored at 4
 °
C 
Bicarbonate-buffered solution 
NaCl 119 mM 
KCl   5 mM 
CaCl2 1.5 mM 
MgSO4 1 mM 
NaHCO3 26 mM 
Glucose 10 mM 
 gassed with 95% O2/5% CO2 during use 
 
Calibration buffer 
KCl 135 mM 
N-methyl-D-glucamine 20 mM 
MgSO4 4 mM 
Glucose 10 mM 
HEPES (buffer substance) 30 mM 
Nigericine 10 nM 
 pH adjusted to 6.6; 6.8; 7.0 or 7.4 
stored at 4 
°
C 
 
 
Table 9: Buffers used for intracellular pH 
measurements 
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at least 1 h or stored for at least two weeks at -20 
°
C. The cells were then washed twice with 0.5% 
Tween-20 in PBS and incubated with 300 µM RNaseA for 15 min at 37 
°
C. Next, one volume of 200 
µM propidium iodide was added, and samples were analyzed by flow cytometry after 10 min 
incubation in the dark. 
2.10.2.3 Annexin V/Propidium iodide apoptosis assay 
In healthy cells, the phosphatidylserines of the plasma membrane face the intracellular compartment. 
Early in apoptosis, they flip towards the extracellular compartment and can, therefore, bind Annexin V 
(Cat Nr. 31490013, ImmunoTools, Germany). Alternatively, late apoptotic or necrotic cells with 
damaged plasma membrane are leaky and allow annexin V bind to phosphatidyl serines from the inner 
side of the membrane as well. The damaged plasma membrane is also permeable to propidium iodide, 
which stains double stranded nucleotide chains. Therefore, viable cells are neither stained by annexin 
V nor propidium iodide. Early apoptotic cells are only annexin V positive, whereas apoptotic and 
necrotic dead cells are positive for both annexin V and propidium iodide. 
For this assay, the supernatant was pooled with the washing fractions and the trypsinized cell 
suspension. The cells were washed twice with PBS (centrifuged in between for 6 min at 500 g). 1 x 
10
5
 cells were resuspended in 100 µl binding buffer (140 mM NaCl, 2.5 mM CaCl2, 10 mM, pH 
adjusted to 7.4) with 2.5 µl Annexin V-FITC and 2.5 µl Propidium iodide (50 µg/ml) and incubated in 
the dark for 15 min. Afterward, the suspension was diluted with 300 µl PBS, and the samples were 
analyzed by flow cytometry. 
2.10.2.4 Staining of intracellular proteins for flow cytometry 
The cells were washed with warm PBS and fixed with 0.5% PFA for 2-3 min on ice. Afterward, the 
cells were trypsinized, washed twice with PBS (centrifuged in between for 6 min at 500 g) and 
blocked/permeabilized (in 0.2% BSA-c and 0.06% Saponin in PBS) for 30 min at RT. Primary 
antibodies were added, and the incubation continued for another 30 min. After a washing step, the 
cells were incubated with fluorophore-conjugated secondary antibodies (diluted in 0.2% BSA-c and 
0.06 Saponin in PBS) for 45 min at RT. After washing away the secondary antibodies, the cells were 
resuspended in PBS and analyzed by flow cytometry. CD31 was stained in parallel with NHE1, for 
which cell permeabilization is necessary since the antibody (NHE11-A, Alpha Diagnostik) recognizes 
an intracellularly located antigen. 
2.10.3 Immunocytochemistry and F-actin staining 
Cells that were grown on glass coverslips coated with 0.2% gelatine were washed with HEPES-
buffered solution and fixed with 4% PFA at RT. Afterward, the cells were washed with PBS and 
permeabilized for 5 min with 0.1% Triton in PBS and blocked with 0.2% BSA-c and 5% goat serum in 
PBS with 0.1% Triton for 30 min. Coverslips were incubated with fluorophore-labeled Phalloidin (not 
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an antibody;Cat No: A12379, Invitrogen) and washed subsequently for 30 min. The incubation with 
primary antibodies was done for 1 h at RT or overnight at 4 
°
C. After washing away the primary 
antibody, the samples were incubated with fluorophore-conjugated secondary antibodies for 45 min at 
RT. The cells were then stained with 4',6-diamidino-2-phenylindole (DAPI, 1 µg/ml in PBS) for 10 
min, embedded with FluoromoutG, and the slides were stored at 4 
°
C until microscopic analysis. The 
coverslips were washed with PBS between each step. 
Table 10: Antibodies for Immunofluorescence 
Antigen Type (IgG) Application Dilution Cat. Nr. Vendor 
CD31 rat, monoclonal MLEC purity 1 : 25 550274 BD Pharmingen 
CD31 rabbit, polyclonal Matrigel plug assay 1 : 200 AP06560PU-N Acris Antibodies 
NHE1 mouse, monoclonal Cytochemistry 1 : 250 Sc136239 Santa Cruz 
Rabbit IgG goat, polyclonal Alexa Fluor 488 1 : 250 A11034 Molecular Probes 
Mouse IgG goat, polyclonal Cy3 1 : 200 A10521 Life Technologies 
Rat IgG goat, polyclonal Cy5 1 : 100 AP136S Millipore 
 
2.10.4 Staining of Matrigel plugs 
Matrigel plugs excised from mice were fixed overnight with IHC Zinc Fixative (Cat No: 550523, BD 
Pharmingen) and dehydrated in a Hystokinette (MICROM STP 120 Thermo Fischer Scientific) with 
the following protocol: 2x 1 h in 70% ethanol, 1 h 96% ethanol, 2x 2 h in 96% ethanol, 2x 2 h in 99% 
ethanol, 1 h in ethanol:xylene 2:1, 1 hour in ethanol:xylene 1:2, 1 h in xylene, 2 h in melted paraffin 
and another 3 h in a second vessel with melted paraffin. Finally, the plugs were embedded in paraffin 
blocks using the MICROM EC 350-1&2 (Thermo Fischer Scientific). Afterward, 5 μm sections were 
prepared from each plug using the MICROM HM 335 (Thermo Fischer Scientific) and Feather blades 
(R35; Feather Safety Razor CO.) and mounted on polysine-coated microscope slides (Gerhard Menzel 
GmbH). The slides were stored at RT.  
The prepared sections on the slides were deparaffinized in xylene 3x 10 min, and rehydrated in 
subsequent 99%, 96%, 70% and 50% ethanol steps for 5 min each and finally in distilled water. The 
sections were then treated for antigen retrieval in pre-warmed citrate-buffered solution (10 mM tri-
Sodium citrate dihydrate; pH 6.0) for 12 min in a microwave at 630 W. The sections were cooled to 
RT, washed with PBS and permeabilized with 0.01% Triton in PBS for 8 min. The slides were then 
mounted on Shandon cassettes (Thermo Fischer Scientific). After 30 min incubation in blocking 
solution (0.01% Triton, 10% goat serum, 0.25% BSA-c in PBS), the sections were subjected to 
immunofluorescence staining with an anti-CD31 antibody for 2 h and an Alexa Fluor 488 labeled 
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secondary antibody for 30 min at RT. The sections were then embedded with FluoromountG and 
covered with coverslips (0.17+/- 0.01mm, selektiert; Gerhard Menzel GmbH). 
2.10.5 Immunostaining of mouse tissues 
Mice were anesthetized by intraperitoneal injection of a fentanyl (0.05 mg/kg) and Medetomidine (0.5 
mg/kg) mixture. The chest was then opened, and a cannula was inserted into the left ventricle to 
perfuse the mouse with 4% PFA for 3 min. Afterward, the mice were left for another 10 min to be 
fixed with the perfused PFA, and several organs were collected. The organs were washed with PBS 
and dehydrated in 30% sucrose in PBS overnight at 4 
°
C. The organs were then embedded with 
Tissue-Tek (Ref. 4583, Sakura) and stored at -80 
°
C until further processing. 10 µm thick cryosections 
were prepared on adhesive slides using the Leica CM 1850 Cryostat (Cat. No. 0810401; Histobond 
Marienfeld) and stored at -20 
°
C. 
For immunostaining, the sections were dipped in PBS to wash-away the Tissue-Tek and placed on 
Shandon cassettes. The sections were blocked with 5% normal goat serum and 0.1% Triton-X in PBS 
for 30 min at RT. Primary and secondary antibodies were diluted in blocking solution as well. After 
washing with PBS, the sections were incubated with primary antibody overnight at 4 
°
C, followed by 
incubation with a fluorophore-conjugated secondary antibody for 45 min at RT, and then stained with 
DAPI (1 µg/ml PBS) for 10 min at RT. After each step, the sections were washed with PBS. No 
staining was necessary for Tomato, as the protein retains its fluorescence activity throughout the 
histochemical procedure. Finally, the sections were covered with coverslips (0.17+/- 0.01mm, 
selektiert; Gerhard Menzel GmbH, Germany) after embedding with FluoromountG, and imaged with a 
confocal microscope (Leica TCS SP5; Wetzlar) under a 400x magnification. (David Böhm has helped 
with the workload during cryosectioning and staining of the mouse tissues) 
2.11 In-vivo angiogenesis with Matrigel plug assay 
PBS for paraformaldehyde 
Stock I (base)  
Na2HPO4 anhydrous 1 M 
NaCl 1.36 M 
Stock II (acid)  
NaH2PO4 x H2O 1 M 
NaCl 1.36 M 
Mixing  
Mix 700 ml H2O with 17.5 ml Stock II 
Titrate to pH 7.4 with Stock I 
Fill up to 1 L with H2O 
 
4% Paraformaldehyde (PFA) 
Dissolve 40 g PFA in 400 ml H2O at 60 
°
C, 
clarify soltution with 4 drops of NaOH H2O 
and fill-up to 500 ml H2O 
Mix 500 ml PBS for PFA with 500 ml dissolved 
PFA, filter and store at -20 
°
C 
 
Table 11: Preparation of 4% PFA in PBS solution 
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Matrigel is extracellular matrix obtained from mouse sarcomas and processed to reduce its growth 
factor content. It is stored at -20 
°
C and thawed on ice before use. After subcutaneous injection, the 
matrigel solidifies at body temperature forming a plug into which blood vessles from the surrounding 
tissue can grow. Therefore, the matrigel plug assay is used to study angiogenesis in vivo.  
The Matrigel plug assay was approved by the local administrative institution (Thüringer Landesamt 
für Verbraucherschutz, Bad Langensalza, Germany) under the application document “Reg.-Nr. 02-
028_13_Regulation und Funktion NHE1 in Endothelzellen_Heller“ and the experiment was performed 
according to the guidelines of the animal welfare committee of the State of Thuringia. 
Two separate matrigel plug experiments were performed. In the first one angiogenesis was studied 
with constitutive Nhe1
-/-
 mice and wildtype littermates that were 10-16 days old. In the second 
experiment angiogenesis was studied in 12-15 weeks old endothelial cell-specific Nhe1
-/-
 mice of the 
genotype Nhe1
flox/flox
; VE-Cadherin-Cre
+
, while Nhe1
flox/flox
 littermates without Cre were used as 
control animals. All the mice were of mixed 129SvJ/C57BL/6 background, which were backcrossed 
for ten generations with C57BL/6 mice in case of the constitutive Nhe1
-/-
 mice, or three generations for 
the endothelial cells specific Nhe1
-/-
 mice. 
Animals were anaesthetized by intraperitoneal injection of a fentanyl (0.05 mg/kg) and Medetomidine 
(0.5 mg/kg) mixture and ice-cold Matrigel was injected subcutaneously on each flank; supplemented 
with heparin (400 μg/ml; 12.7 units/ml) and VEGF (400 ng/ml) for the right flank. Less than 250 μl 
Matrigel could be injected on each flank in the small pups, compared to 500 μl for the older mice. Few 
minutes later, the mice were injected intraperitoneally with an antidote mixture of Atipamezole (2.5 
mg/kg), Flumazenil (0.5 mg/kg) and Naloxone (1.2 mg/kg). Mice were sacrificed after seven days of 
incubation. Excised plugs were processed as described in section 2.10.4. Sections from the experiment 
with constitutive Nhe1
-/-
 mice were imaged with a confocal microscope (Leica TCS SP5) at a low 
magnification (50x) in order to capture the whole plug section in one picture. The sections from the 
experiment with endothelial cell-specific Nhe1
-/-
 mice were scanned at a 200x magnification with an 
epifluorescent microscope (Nikon Eclipse Ti) and single images were stitched automatically. The 
Nikon Perfect Focus System was used to keep subsequent pictures in focus. To obtain a representative 
evaluation for each plug, two sections from at least four levels were collected, discarding 100 μm 
between each level. The images were analyzed in ImageJ software using Otsu automatic threshold and 
CD31-positive pixels were normalized against the manually defined plug area. The normalized values 
for each level were used to calculate the final average for the plug. 
2.12 Statistical analysis 
The information on the number of subjects used and the statistical test applied are included in 
respective figure legends. Paired two-tailed Student’s t-test or two-way repeated measurements 
2 Methods 
38 
 
ANOVA were used to calculate significance after analyzing variance with Holm-Sidak correction for 
multiple comparisons. p<0.05 was considered significant. Data in the figures are represented as mean 
± SEM of independent experiments performed with cells from separate preparations. Additionally, 
some figures contain data from individual experiments depicted as gray lines. 
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3 Results 
3.1 NHE1 downregulation in endothelial cells 
In order to develop a tool for investigating the functional importance of NHE1 in endothelial cells, 
downregulation of the protein by applying the RNAi technology was established. The NHE1 protein 
was detected in MLEC and HUVEC as a band of around 110 kDa after SDS-PAGE separation and 
western blotting (Figure 3-1A). The antibody (mab3140; EMD Millipore, USA) also recognized a 
second band at a slightly larger size but this was most likely unspecific, because it was also observed 
in MLEC from the constitutive Nhe1-knockout (Nhe1
-/-
) mice. A pool of four different specific siRNA 
sequences at a total concentration of 0.5 µg/ml (37 nM) was applied while the control cells received 
the same amount of scRNA. Figure 3-1C shows that the siRNA transfection resulted in efficient 
knockdown of NHE1 by 75% on average. NHE1 levels were decreased as soon as 24 h and remained 
low for at least 120 h after transfection. Consequently, the in vitro experiments in HUVEC were 
performed after downregulation of NHE1 by transfection of siRNA and within the described time.   
 
Figure 3-1: Downregulation of NHE1 in HUVEC 
NHE1 was detected at approximately 110 kDa with an unspecific band at a slightly larger size recognized by the 
same antibody (A). Low doses of 0.5 ug/ml siRNA pool (four siRNA sequences) sufficiently downregulated 
NHE1 (B) for at least 120 h (C), a timeframe used for all experiments. CsiR (scRNA transfected HUVEC), NsiR 
(NHE1 siRNA transfected HUVEC), n=3 for C, * p<0.05 vs. CsiR of the respective time point, Student´s t-test. 
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3.2 NHE1 in regulating pHi of endothelial cells 
NHE1 regulates the intracellular proton concentration. Therefore, the pHi recovery of acid loaded cells 
was measured to functionally verify NHE1 knockdown and to study its involvement in endothelial cell 
pHi regulation. Cells cultured on glass coverslips were perfused with HEPES-buffered solution to 
block the contribution of HCO3
-
-dependent transporters. HUVEC treated with NHE1 siRNA (NsiR) 
had a lower basal pHi than control cells treated with non-targeting siRNA (CsiR) (CsiR: 7.24±0.04; 
NsiR: 7.09±0.04), and recover their pHi at a significantly slower rate after cytoplasmic acidification 
with the ammonium prepulse technique (CsiR: 0.52±0.07 δpH/min; NsiR: 0.22±0.03 δpH/min) (Figure 
3-2). The reason for the remaining recovery is unclear, but might be due to maximal activation of 
residual NHE1 protein since downregulation with siRNA incomplete (see section 3.1).  
 
Figure 3-2: Intracellular pH measurements in HUVEC 
Traces of pHi measurements in HEPES-buffered solutions are shown in (A). NHE1 knockdown reduced basal 
pHi (B) and pHi recovery after acidification with ammonium prepulse protocol (B). n=7 for CsiR (scRNA 
transfected HUVEC), n=10 for NsiR (NHE1 siRNA transfected HUVEC), p<0.05, * vs. CsiR, Student’s t-test. 
3.3 In vitro characterization of NHE1 in endothelial cell functions 
3.3.1 The role of NHE1 in HUVEC proliferation and survival 
Intracellular pH regulation by NHE1 was shown to affect proliferation and survival of different cell 
types. Therefore, NHE1 knockdown approach was used to evaluate whether the same applies to 
HUVEC. To this purpose, cell cycle analysis, annexin V and propidium iodide stainings and cell 
counting were performed in two different sets of experiments. In the first one, HUVEC were cultured 
in growth medium and analyzed within 48 h after transfection without additional stimulation. In order 
to mimic similar conditions to the spheroid assay (see section 3.3.3), in the second set HUVEC were 
transfected, reseeded 48 h later and stimulated with 50 ng/ml VEGF 24 h after reseeding (time 0 h). 
Further analyses were performed in the next two days (time 24 h and 48 h after stimulation or 96 or 
120 h after transfection, respectively). 
The first series of experiments showed that downregulation of NHE1 by siRNA repressed cell growth. 
Alterations in the cell cycle between CsiR and NsiR cells were observed 24 h after transfection. NsiR 
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cells showed a higher proportion in the G0/G1 phase of the cell cycle and a lower proportion in the S 
plus G2/M phase (61±1% and 40±3%, respectively) when compared to CsiR cells (42±2% and 57±1%, 
respectively) suggesting a lower proliferative capacity in NHE1-depleted cells. Consequently, 48 h 
after transfection the cell number in NsiR samples was significantly reduced by 35%. At the same time 
point, control cells approached confluence and proliferation decreased, thus no difference was 
observed anymore in the cell cycle analysis. Since NsiR cells were viable in growth medium over 48 h 
after transfection, the difference in cell count cannot be explained by cell loss. 
 
Figure 3-3: HUVEC proliferation in growth medium 
Cells were stained with propidium iodide and analyzed by flow cytometry for cell cycle distribution at 24 and 48 
h after transfection (A). 48 h after transfection, cells were counted (B) or analyzed for cell death and apoptosis 
(C). NHE1 knockdown reduced cell cycle progression within 24 h, which was reflected in lower cell count at 48 
h after transfection. The number of apoptotic and dead cells was comparable between samples (C). CsiR (scRNA 
transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC), n=3 (A, C), n=6 (B); p<0.05, § vs. CsiR, 
Student’s t-test. 
 
In the second series of experiments, transfected cells were reseeded to determine the cell growth curve 
after VEGF stimulation in low serum medium (2% FCS). VEGF induced a significant increase in cell 
number in both control and NHE1 siRNA-treated HUVEC after 48 h. However, NHE1 knockdown 
reduced VEGF-stimulation HUVEC proliferation after by 24%, while the same trend was observed for 
unstimulated samples (Two Way RM ANOVA, p<0.01 for VEGF, p=0.053 for unstimulated). 
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Evaluation of the sub-G1 population in cell cycle analysis was used to estimate cell survival. Figure 
3-4B shows that VEGF stimulation led to a considerable decrease of particles in the sub-G1 fraction in 
control conditions and after downregulating NHE1, which indicates a potent survival effect in both 
situations. Thus, while VEGF was only a weak stimulus for HUVEC proliferation, it had strong 
antiapoptotic effects. These effects were seen 24 and 48 h after stimulation, even though the 
proportion of apoptotic cells was much higher after 48 h. The latter is due to the low serum conditions 
in this experiments leading to induction of apoptosis. Although the number of dying NHE1-siRNA-
treated cells tended to increase compared to control cells, the difference was statistically not 
significant.  
 
Figure 3-4: VEGF-induced HUVEC proliferation 
48 h after transfection with siRNA, cells were reseeded for growth curve (A) and sub-G1 analysis (B). Cells were 
starved for 4 h in low serum medium, to which VEGF was added. Samples were analyzed at the time of 
stimulation (0 h) as well as 24 and 48 h later. HUVEC proliferated less upon VEGF stimulation if NHE1 was 
downregulated. Additionally, sub-G1 analysis showed that the survival effect of VEGF was comparable between 
control and NHE1-depleted cells. CsiR (scRNA transfected HUVEC), NsiR (NHE1 siRNA transfected 
HUVEC), n=7 (A), n=3 (B); p<0.05, * vs. respective unstimulated control, § vs. CsiR VEGF, Two Way RM 
ANOVA. 
 
Taken together, NHE1 depletion slowed down HUVEC proliferation both in growth medium 
immediately after transfection and later after VEGF stimulation in low serum medium. The survival 
effect of VEGF did not seem to be affected by NHE1 knockdown. 
3.3.2 The role of NHE1 in HUVEC migration 
NHE1 has been shown to be involved in cell migration in different cell types, in which mainly the 
effect of NHE1 overexpression was observed. In these studies NHE1 was localized at the leading edge 
of migrating cells [49, 103]. In the current study, similar observations were made. Figure 3-5 shows 
that NHE1 is co-stained with actin at cell protrusions in a single spontaneously migrating endothelial 
cell. In a confluent HUVEC monolayer NHE1 is stained at cell-cell contacts.  
3 Results 
43 
 
 
Figure 3-5: Immunocytochemistry of NHE1 in HUVEC 
NHE1 is stained at the cell-cell contacts of a confluent endothelial cell culture (A). In a spontaneously migrating 
cell of a subconfluent culture, NHE1 is co-stained with actin at plasma membrane protrusions (B). CsiR (scRNA 
transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC). 
 
Based on this observation, three different assays were used to study the role of NHE1 in HUVEC 
migration: wound healing, transwell and chemotaxis assay.  
3.3.2.1 Transwell migration assay 
Cells transfected with siRNA were starved for 3 h in serum-free medium and stimulated with 50 ng/ml 
VEGF or 0.1 µM S1P for 4 h in a transwell system. Thereafter, cells were fixed, stained and the 
number of migrated cells was analyzed. Basal migration was similar between CsiR and NsiR cells 
(Figure 3-6). In contrast to what was expected from literature data [104-106], VEGF did not stimulate 
HUVEC migration neither in control cells nor in NHE1-depleted cells under the experimental 
conditions used. However, S1P potently induced migration. The migratory response was significantly 
reduced by 31% by NHE1 downregulation, suggesting that NHE1 is an important factor for HUVEC 
migration. 
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Figure 3-6: Transwell migration assay 
HUVEC transfected with siRNA were seeded on transwell inserts and either left to migrate spontaneously, or 
stimulated with VEGF (50 ng/ml) or S1P (0.1 µM) for 4 h. Representative images are shown in (A). VEGF was 
unable to induce migration in the conditions used, whereas S1P was a strong stimulus and its effect was 
dampened when NHE1 was downregulated (B). CsiR (scRNA transfected HUVEC), NsiR (NHE1 siRNA 
transfected HUVEC), n=5, p<0.001, * vs. unstimulated, § vs. CsiR S1P, Two Way RM ANOVA. 
3.3.2.2 Wound healing assay 
HUVEC were seeded at high confluency (1.5 x 10
5
 cells/cm
2
) on ibiTreat culture dishes with inserts. 
After removing the insert, a cell-free area between two monolayers was created, the so-called wound, 
into which cells could migrate. After preincubation in low serum medium for 2 h, cells were either left 
unstimulated or stimulated with VEGF (50 ng/ml) or S1P (0.1 µM). After six hours, migration slowed 
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down when both sides of the wound reached each other and the wound closed completely within 12-16 
h in the stimulated samples. Therefore, the healing was quantified by counting cells in 2 h intervals 
within 6 h after stimulation. Whereas VEGF only slightly induced wound healing, S1P significantly 
stimulated healing by twofold (Figure 3-7). Importantly, NHE1 knockdown significantly inhibited 
wound closure by 21% in S1P-stimulated samples. This further confirms NHE1´s involvement in the 
migratory process in HUVEC. It was observed though that the unstimulated cells in the very dense 
monolayer died abundantly under low serum conditions, thus the VEGF and/or S1P effect on wound 
closure could be partly due to the survival effect as well. 
 
Figure 3-7: Wound healing assay 
HUVEC transfected with siRNA were seeded on ibiTreat culture dishes with wound healing inserts. After 
removing the inserts, cells were starved for 2 h in low serum medium to which VEGF (50 ng/ml) or S1P (0.1 
µM) was then added. Subsequently, migration was tracked over 6 h by counting the cell nuclei in the wound area 
(A). Whereas S1P promoted wound closure, VEGF had only a slight effect (B). NHE1 knockdown significantly 
slowed down the healing in S1P-stimulated samples (B). CsiR (scRNA transfected HUVEC), NsiR (NHE1 
siRNA transfected HUVEC), n=6, p<0.05, * vs. respective unstimulated control, § vs. CsiR S1P, Two Way RM 
ANOVA. 
3.3.2.3 2D chemotaxis assay 
As a third approach, 2D chemotaxis slides (ibidi, ibiTreat) were used to test how HUVEC react to 
gradients of VEGF (50 ng/ml) or S1P (0.1 µM). As expected, net cell movement in the unstimulated 
samples is close to zero for both the parallel (ǁ) and transverse axis (⏊). VEGF was unable to induce 
polarization and movement towards the gradient, while 24 h of S1P stimulation led to cell polarization 
and ~150 µm net movement towards the stimulus (Figure 3-8). S1P-induced responses regarding 
velocity and forward migration index (FMI) in the parallel axis were reduced in NHE1-depleted cells 
although this did not reach statistical significance. However, a 32% significant inhibition of the 
displacement of center of mass was seen in NHE1 knockdown HUVEC, again indicating negative 
regulation of migration by NHE1 (Figure 3-9). Overall, the three different approaches suggest that 
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NHE1 is important in migration of endothelial cells, as its downregulation inhibits S1P-induced 
migration. 
 
Figure 3-8: Representative traces of 2D chemotaxis 
Migrating HUVEC were traced moving within the chemotactic gradient of VEGF (50 ng/ml) or S1P (0.1 µM) or 
in the absence of a stimulus. Cells migrating to the left of the parallel (ǁ) axis are labeled in red, whereas cells 
migrating towards the stimulus in green. S1P, but not VEGF, was able to induce chemotaxis. CsiR (scRNA 
transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC). 
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Figure 3-9: 2D chemotaxis assay 
HUVEC transfected with siRNA were seeded on ibidi chemotaxis slides (ibiTreat surface) and 4 h later medium 
was changed to low serum medium. After 2 h VEGF (50 ng/ml) or S1P (0.1 µM) was added on one side of the 
chamber and migration was tracked within 24 h. Approximately 30 cells per chamber were traced to calculate 
migration velocity (C) as well as the displacement of Center of Mass (COM) (A) and the Forward Migration 
Index (FMI) (B) for both the parallel (ǁ) and the perpendicular (⏊) axis. NHE1 knockdown reduced HUVEC 
chemotaxis after S1P stimulation as seen for the displacement of COM. CsiR (scRNA transfected HUVEC), 
NsiR (NHE1 siRNA transfected HUVEC), n=3 for unstimulated and VEGF, n=8 for S1P; p<0.05, * vs. 
respective unstimulated control, § vs. CsiR S1P parallel axis, Student’s t-test. 
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3.3.3 The role of NHE1 for in vitro angiogenesis 
Based on the data from proliferation and migration experiments, NHE1 was further tested for 
potentially participating in the complex process of angiogenesis. To this end, endothelial spheroids 
were embedded in a 3D fibrin gel, where they produce capillary-like sprouts upon angiogenic 
stimulation, which was quantified as a measure for angiogenesis in vitro. Spheroids from control or 
NHE1-depleted HUVEC were stimulated with two different VEGF concentrations, 10 or 50 ng/ml. 
After 48 h, sprout number and length were quantified. Unstimulated spheroids did not sprout, while 
VEGF induced a clearly visible angiogenic response (Figure 3-10). The number of VEGF-stimulated 
sprouts was significantly reduced by 56% when NHE1 was downregulated (Figure 3-10B). Similarly, 
the average sprout length was significantly shorter by 20% (Figure 3-10C). Taken together, as 
hypothesized from proliferation and migration data, NHE1 supported angiogenesis in vitro since its 
downregulation inhibited VEGF-induced sprouting. 
 
 
Figure 3-10: Importance of NHE1 in VEGF-induced spheroid sprouting 
Spheroids generated from control or NHE1siRNA-transfected HUVEC were left unstimulated in low serum 
medium or stimulated with two different VEGF concentrations (10 ng/ml or 50 ng/ml) and analyzed after 48 h 
(A). NHE1 downregulation dampened both VEGF-induced sprout number (B) and length (C). CsiR (scRNA 
transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC), n=5, p<0.05, * vs. respective unstimulated 
control, § vs. CsiR, Two Way RM ANOVA. 
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3.4 NHE1 in endothelial cell signaling 
3.4.1 Interaction between NHE1 and VEGF signaling 
In order to understand the cellular mechanisms of how NHE1 may affect VEGF-induced angiogenesis, 
VEGF-induced signaling and gene expression were analyzed in NHE1-depleted HUVEC using 
western blot analysis and qPCR, respectively. The analysis of VEGF-induced signaling cascades did 
not show differences between control cells and NHE1-depleted cells. As seen in Figure 3-11: VEGF-
induced VEGFR2 phosphorylation, VEGF-induced VEGFR2 phosphorylation was quantitatively 
similar in NsiR and CsiR HUVEC (Figure 3-11).  
 
Figure 3-11: VEGF-induced VEGFR2 phosphorylation 
HUVEC were starved for 4 h in serum-free medium and then for 30 min in HEPES-buffered solution 
supplemented with 0.25% HAS. Afterwards, cells were stimulated for the respective time points with 50 ng/ml 
VEGF. NHE1 downregulation did not alter the quantity or the kinetics of VEGFR2 phosphorylation. CsiR 
(scRNA transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC). 
 
Moreover, extent and kinetics of phosphorylation of four downstream enzymes were similar in NsiR 
and CsiR HUVEC after VEGF stimulation:  pT
172
-AMPK, pS
1196
-eNOS, pT
202/204
-ERK 1/2 and pS
473
-
AKT (Figure 3-12). Both controls and NHE1-depleted cells showed a clear transient phosphorylation 
of AMPK, ERK1/2 and eNOS with peaks at two to five minutes after VEGF stimulation. The 
phosphorylation of AKT showed a maximum at ten to fifteen minutes and was also comparable 
between NsiR and CsiR HVUEC. 
To understand whether NHE1 downregulation in HUVEC alters the expression of angiogenic genes, a 
qPCR angiogenesis array was performed. The 84 genes included in this array were grouped in quickly 
induced and slowly induced ones and evaluated after 4 or 24 h of VEGF treatment, respectively. This 
grouping followed an extensive review of the literature for the kinetics of gene expression in HUVEC 
after VEGF stimulation. Surprisingly, VEGF induced more than twofold changes in the expression of 
only 13 genes, which are depicted Figure 3-13A. 
A limited number of genes was differentially expressed in HUVEC when NHE1 was downregulated 
and cells were stimulated with VEGF or kept unstimulated (Figure 3-13B). These include genes for 
angiopoietin 1 and 2 (ANGPT1, ANGPT2), brain-specific angiogenesis inhibitor 1 (BAI1), tissue 
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factor (F3), the chemokines CXCL10 and interleukin 8 (IL8), the matrix metalloprotease 9 (MMP9), 
plasminogen activator inhibitor-1 (PAI-1) and the S1P receptor 1 (S1PR1). For instance, under basal 
conditions an upregulation in NHE1-depleted cells was seen for ANGPT1 and a downregulation for 
CXCL10 and PAI-1.  
  
 
Figure 3-12: VEGF-induced signaling after NHE1 downregulation 
Phosphorylation of several downstream targets of VEGFR2 was monitored over 30 min of stimulation with 
50 ng/ml VEGF. Cells were first starved in serum-free medium for 4 h and incubated further for 30 min in 
HEPES-buffered solution supplemented with 0.25% HSA, in which VEGF was then added. NHE1 
downregulation did neither alter the quantity nor the kinetics of phosphorylation of AMPK, eNOS , ERK1/2 (all 
n=4) and AKT (n=2). p<0.05, *vs. respective unstimulated control (0 min), Student´s t-test. pT (phospho 
threonine), pS (phospho serine). CsiR (scRNA transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC).  
AMPK: AMP-activated protein kinase, eNOS: endothelial nitric oxide synthase, ERK 1/2: extracellular signal-regulated kinase 1/2, AKT: 
protein kinase B. 
 
Differences in VEGF-induced effects between control and NHE1-depleted cells were seen for 
CXCL10 (stronger inhibition in response to VEGF) and F3, MMP9 and IL8 (lower stimulation in 
response to VEGF). However, in general, the differences were not striking and most of these genes did 
not reach the twofold change threshold.  The strongest effect was seen for ANGPT1 (twofold), but this 
result could not be reproduced with different primers (data not shown). Nevertheless, the identified 
genes could be promising to be analyzed at a different VEGF stimulation time-point and with other 
cell batches in further experiments. 
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Figure 3-13: VEGF regulation of gene expression during angiogenesis 
HUVEC were stimulated with VEGF (50 ng/ml) for 4 or 24 h and the expression of 84 angiogenesis related 
genes was analyzed with a qPCR angiogenesis array. In the conditions used in vitro, VEGF altered 13 genes by 
more than twofold (A). NHE1 knockdown seems to moderately influence the expression of a number of genes 
(B). Fold change: (2^(-∆∆Ct)) of the Test vs. Control, upregulation >1, downregulation <1. CsiR (scRNA 
transfected HUVEC), NsiR (NHE1 siRNA transfected HUVEC). 
IL1β: interleukin 1β, NOTCH4: neurogenic locus notch homolog protein 4, PGF: placental growth factor, ANGPT1: angiopoietin 1, 
ANGPT2: angiopoietin2, CXCL6: chemokine (C-X-C motif) ligand 6, FGF2: fibroblast growth factor 2, FIGF: c-fos induced growth factor, 
IGF1: insulin-like growth factor 1, IL6: interleukin 6, MDK: midkine, PTGS1: prostaglandin-endoperoxide synthase 1, TGFB2: 
transforming growth factor beta 2, TIMP3: TIMP metallopeptidase 3, BAI1: brain-specific angiogenesis inhibitor 1, CXCL10: chemokine 
(C-X-C motif) ligand 10, F3: tissue factor, MMP9: matrix metalloproteinase-9 precursor, PAI-1: plasminogen activator inhibitor-1, IL8: 
interleukin 8, S1PR1: sphingosine-1-phosphate receptor 1. 
3.4.2 S1P signaling in NHE1-depleted cells 
Since knockdown of NHE1 in HUVEC affected S1P-induced migration, the effect on S1P signaling 
was also checked. Therefore, cells with normal and downregulated NHE1 were time-dependently 
stimulated with S1P and the phosphorylation of several downstream targets of S1P receptor was 
monitored. S1P induced a fast phosphorylation of eNOS, ERK1/2 or AKT reaching maximal values 
after 2 min (Figure 3-14). NHE1 knockdown did not alter the extent or the dynamics of S1P-induced 
phosphorylation events. 
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Figure 3-14: S1P-induced signaling after NHE1 downregulation 
Phosphorylation of several downstream targets of the S1PR1 was monitored over 30 min of stimulation with 0.1 
µg/ml S1P. NHE1 down-regulation did neither alter the quantity nor the kinetics of phosphorylation of eNOS, 
ERK1/2 (all n=4) and AKT (n=2). pT (phospho threonine), pS (phospho serine). CsiR (scRNA transfected 
HUVEC), NsiR (NHE1 siRNA transfected HUVEC), p<0.05, *vs. respective unstimulated control (0 min), 
Student´s t-test. 
eNOS: endothelial nitric oxide synthase, ERK1/2: extracellular signal-regulated kinase 1/2, AKT: protein kinase B. 
 
 
3.5 NHE1 expression under growth factor treatment and hypoxia  
In addition to studies of signaling and gene expression, growth factor effects on NHE1 expression 
were analyzed (Figure 3-15). 50 ng/ml VEGF or 0.1 µM S1P did not increase NHE1 expression after 
24 or 48 h of incubation compared to control medium with 2% FCS. However, a moderate increase of 
NHE1 expression was observed upon serum depletion (comparing medium supplemented with 17.5% 
FCS, 2.5% human serum and mitogen and medium with 2% FCS, respectively) (not significant). 
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Endothelial cells undergo hypoxic stress, for instance when sprouting into hypoxic areas, and respond 
with changes in gene regulation mediated by HIF1 or HIF2. Therefore, the effect of hypoxia (1% 
O2 experimentally) on NHE1 expression in HUVEC was investigated. Figure 3-16 shows that HUVEC 
accumulate both HIF1 and HIF2 after 8 h of hypoxia and maintain the expression of both 
transcription factors for up to 72 h. During this time, HIF1 expression decreased while HIF2 
remained equally high. An increased HIF1/2 expression was also seen after incubating HUVEC 
with CoCl2, a chemical inducer of HIF. Importantly, hypoxia led to a slow increase of NHE1 
expression (Figure 3-16). After 72 h NHE1 protein was significantly doubled in hypoxic samples 
compared to normoxic controls. In addition, CoCl2 had the same effect like hypoxia.  
Figure 3-15: The effect of growth factors on 
NHE1 protein levels 
HUVEC were cultured in low serum medium (2% 
FCS) only or supplemented with VEGF (50 ng/ml) or 
S1P (0.1 uM) for 24 and 48 h. Growth medium 
(containing 17.5% FCS, 2.5% human serum, and 
mitogen) was used as an additional control. Neither 
VEGF nor S1P increased NHE1 expression compared 
to 2% FCS medium. Under growth factor rich 
conditions NHE1 expression was slightly lower 
compared to low serum medium. n=3. 
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To check whether the increased expression of NHE1 in hypoxia was mediated by HIF, an siRNA 
approach was used. Figure 3-17 shows that application of specific siRNAs led to efficient 
downregulation of either HIF1 or HIF2 by approximately 85%. When HIF1 was downregulated, 
the hypoxia-induced NHE1 expression remained high (Figure 3-17). In contrast, downregulation of 
HIF2 prevented the effect of 72 h hypoxia on NHE1 expression suggesting that it was mediated by 
HIF2. Interestingly, the accumulation of HIF1 and HIF2 seems to be interlinked. Upon 
knockdown of HIF2, HIF1 levels significantly raised while HIF2 was moderately increased in 
cells where HIF1 was downregulated. 
 
Figure 3-17: Expression of HIF1α, HIF2α and NHE1 in hypoxia 
HUVEC incubated in hypoxia for 72 h double their NHE1 levels (A). This effect probably depends on HIF2α as 
its knockdown inhibits the increase in NHE1, whereas HIF1α knockdown has no effect. Additionally, HIF1α 
increases two fold if HIF2α is knocked down (B). n=4, p<0.05, * vs. normoxic control, § vs. CsiR and HIF2α 
siRNA hypoxia, Two Way RM ANOVA 
Figure 3-16: NHE1 expression in 
HUVEC under hypoxia (1% O2) 
NHE1 expression increased over time, 
reaching twofold higher levels in hypoxic 
samples compared to normoxic controls after 
72 h. Chemical hypoxia using 100 µM CoCl2 
also increased the amount of NHE1 protein. 
HIF1α and HIF2α were both detectable in 
hypoxia and during chemical hypoxia. 
Whereas HIF1α levels dropped after 8 h, 
HIF2α stayed stable over time. n=4 for 
NHE1, n=3 for HIF1α, n=1 for HIF2 α, 
p<0.05, * vs. normoxic control, Student’s t-
test. 
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To see whether induction of NHE1 in hypoxia is due to metabolites or proteins released into the 
medium upon hypoxia, cells were incubated in hypoxia or normoxia for 72 h and cell culture medium 
(preincubated for pH and O2 adjustment) was refreshed every 24 h (Figure 3-18). The medium 
exchange was able to significantly inhibit the increase in NHE1 expression after 72 h in hypoxia 
suggesting HIF2-mediated NHE1 expression may involve factors released into the medium.  
 
 
 
 
 
 
 
 
 
 
 
3.6 The role of NHE1 for in vivo angiogenesis – Matrigel plug assay 
Since, in vitro data suggested that NHE1 might be important for angiogenesis, a Matrigel plug assay 
was applied as an in vivo approach to study angiogenesis in wild type and constitutive Nhe1
-/-
 mice. 
Ten to sixteen days old mice had to be used, because the constitutive Nhe1
-/-
 mice die between two and 
four weeks. Seven days after subcutaneous injection of Matrigel with or without VEGF, the generated 
plugs were excized and analyzed for the formation of new blood vessels. The latter was done by 
immunofluorescence staining of the endothelial marker CD31 in Matrigel sections and quantified by 
normalizing CD31 positive pixels to the plug area. Due to the low weight of the young mice and 
smaller volume of injected Matrigel, however, some plugs were smaller than required in original 
protocols and did not reach the quality necessary for reliable quantification of vascular endothelium. 
Figure 3-18: Effect of medium exchange on hypoxia-
induced NHE1 expression 
HUVEC were incubated for 72 h under hypoxic condition 
and medium (pre-incubated for pH and O2 equilibration) was 
changed every 24 h. Under these conditions NHE1 levels 
remained comparable to normoxic controls while increased 
NHE1 abundance was seen in samples without medium 
change. n=4, p<0.05, * vs. normoxic control, § vs. hypoxic 
control, Two Way RM ANOVA. 
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Figure 3-19: Matrigel plug assay in constitutive Nhe1
-/-
 mice 
For this experiment 10-16 days old Nhe1
+/+
 (WT) and constitutive Nhe1
-/-
 mice were used. 250 µl of Matrigel 
supplemented with or without VEGF (400 ng/ml) plus Heparin (400 µg/ml) was injected subcutaneously on 
either the right or the left flank, respectively. One week later, plugs were excised and angiogenesis was verified 
by immunofluorescence using an antibody against CD31. A representative figure of a whole plug is given in (B), 
while a thresholded example of a magnified plug part (D) is given in (C). Vessel formation was quantified by 
evaluating eight different sections deriving from four different levels of each plug using the ImageJ software. 
VEGF induced angiogenesis is lower in Nhe1
-/-
 compared to WT mice. n=14, p<0.05, * vs. unstimulated, § vs. 
Nhe1
-/-
 VEGF, Two Way RM ANOVA. 
 
VEGF significantly induced around twofold higher vessel formation in WT mice (Figure 3-19). In 
Nhe1
-/-
 mice significantly fewer vessels were formed in response to VEGF than in WT (22% less for 
plugs supplemented with VEGF). These data confirmed the results obtained in the in vitro spheroid 
assay and underline that NHE1 is likely to support the process of VEGF-induced angiogenesis. 
3.7 The endothelial cell-specific Nhe1-/- mouse model 
3.7.1 Generation and characterization of an endothelial cell-specific Nhe1-/- 
mouse model 
Since constitutive Nhe1
-/-
 mice display a severe neurological phenotype and die early, the model is 
unsuitable for more complex studies of angiogenesis in vivo such as the hind limb ischemia assay. 
Moreover, a constitutive Nhe1
-/-
 model does not deliver specific information on the role of NHE1 in 
endothelial cells. For instance, angiogenesis is not only mediated by endothelial cells, but also by 
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mural or hematopoietic cells. Therefore, one aim of this study was to generate an endothelial-specific 
Nhe1
-/-
 mouse and characterize endothelial function in these mice. 
In order to knockout Nhe1 specifically, two different Cre lines were tested, the Tie2 [98] or the VE-
cadherin-Cre line [97]. First, the efficiency and specificity of gene recombination was evaluated by 
mating Tie2 and VE-Cadherin-Cre lines with a fluorescent reporter line, the Tomato mouse line [99]. 
Figure 3-20 shows that both Cre lines were able to specifically recombine the Tomato-knockin 
reporter allele in endothelial cells since tissue sections of several organs (heart, brain, liver, and 
kidney) showed the Tomato fluorescence at the CD31 positive sites.  
Next, Tie2 or the VE-cadherin-Cre line were mated with the Nhe1
flox/flox
 mouse line. From the 
Nhe1
flox/flox
;Tie2-Cre
+
 (Tie2
+
) mice and the Nhe1
flox/flox
;VE-Cadherin-Cre
+
 (VE-Cadherin
+
) mice 
MLEC were prepared and compared to MLEC from Nhe1
flox/flox 
mice without Cre recombinase (Cre
-
). 
Western blot and flow cytometry analyses were applied since detection by immunofluorescence, 
which would have been the method of choice, was not possible due to a lack of an antibody that 
reliably stains NHE1 in mouse tissue sections.  
For the Tie2
+
 line, western blot analysis suggested that recombination was inefficient, since the NHE1 
protein level in MLEC lysates from Tie2
+ 
and
 
Cre
-
 mice was comparable (Figure 3-21A). Given that 
MLEC cultures also contain non-MLEC that may have a stronger expression of NHE1 and thus may 
cause false-positive NHE1 signals in combined cell lysates, NHE1 staining together with CD31 
staining in flow cytometry was performed (Figure 3-21B). Here, NHE1 expression in cells that co-
express CD31, e.g. endothelial cells, is distinguishable from NHE1 expression in CD31
-
 cells. Figure 
3-21B shows that with this method a clear knockdown of NHE1 in endothelial cells from the 
constitutive Nhe1
-/-
 mice was seen. However, fluorescence intensity for NHE1 in the CD31
+
 
population from Tie2
+
 was only slightly lower than in CD31
+
 cells from Cre
-
 mice (Figure 3-21B). 
Therefore, it can be concluded that the Tie2-Cre
+
 mouse line was not able to efficiently knockout Nhe1 
in MLEC and probably in other endothelial cells as well. 
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Figure 3-20: Immunohistochemistry of organs from Tomato
flox/flox
 mated with Tie2-Cre
+
 or VE-
Cadherin-Cre
+
 
Several organs including brain, heart, kidney and liver were cryosectioned and stained for CD31. Tomato is a 
fluorescent protein and does not require staining. In sections from both Cre-lines, Tomato signal was localized at 
the CD31 positive sites, therefore both Cre-lines were able to recombine the Tomato-floxed allele. No Tomato 
signal was observed in Cre
-
 tissues. 
 
 
Figure 3-21: Detection of NHE1 in MLEC from the Tie2-Cre
+
 line 
(A) Total lung cell lysates (prior to magnetic selection of MLEC) from Tie2-Cre
+
 mice and lysates from MLEC 
after magnetic separation were analyzed by SDS-PAGE and western blotting. (B) MLEC derived from 
constitutive Nhe1
-/-
 mice or the Tie2-Cre
+
 mice were stained for CD31 (endothelial cell marker) and NHE1 and 
analyzed by flow cytometry. While a clear knockout of NHE1 was seen in constitutive knockout mice, Tie2-Cre
+
 
was unable to efficiently knockout Nhe1 in MLEC. n=2 for flow cytometry, n=3 for western blot, n: is the 
number of mice. 
3 Results 
59 
 
In contrast, VE-cadherin
+
 mice showed an efficient knockout of Nhe1 in endothelial cells. No NHE1 
protein was detected by western blot analysis of VE-Cadherin
+
 MLEC (culture purity >95 %) (Figure 
3-22A). Moreover, the CD31
+
 population in VE-cadherin
+
 samples did not show NHE1 expression 
similar to what was seen in MLEC from the constitutive Nhe1
-/-
 mice (Figure 3-22B). MLEC from 
Cre
-
 mice expressed NHE1 similar to WT mice. Additionally, NHE1 fluorescence of CD31 negative 
cells was similar between VE-Cadherin
+
, Cre
-
, and WT mice. This reassures the specificity of NHE1 
knockout in VE-Cadherin
+
 mice. 
 
Figure 3-22: Detection of NHE1 in MLEC from the Nhe1
flox/flox
;VE-Cadherin-Cre
+
 (VE-
Cadherin
+
) line 
(A) MLEC derived from constitutive Nhe1
-/-
 mice or VE-Cadherin
 +
 mice were lysed and analyzed by SDS-
PAGE and western blotting. (B) MLEC from both mice strains were stained for CD31 (endothelial cell marker) 
and NHE1 and analyzed by flow cytometry. VE-Cadherin
 +
 mice show an efficient knockout of Nhe1 in MLEC, 
which is comparable to the one seen in MLEC from constitutive Nhe1
-/-
 mice. The expression of NHE1 in CD31
-
 
cells is unaffected. n=5 flow cytometry, n=3 western blot; n: is the number of mice. 
3.7.2 Functional characterization of MLEC from the endothelial cell-specific 
Nhe1
-/-
 mice 
To confirm knockout of Nhe1 on a functional level, pHi measurements were performed with MLEC 
from Nhe1
flox/flox
;VE-Cadherin-Cre
+
 (VE-Cadherin
+
) and Nhe1
flox/flox
 (Cre
-
) mice (Figure 3-23). 
Measurements were performed in HEPES- or HCO3
-
/CO2-buffered solutions to reveal effects of 
HCO3
-
-dependent transporters. Figure 3-23C shows that in HEPES-buffered solutions basal pHi was 
significantly lower in MLEC from VE-Cadherin
+
 mice, in which NHE1 was not expressed, compared 
to cells from NHE1-containing Cre
-
 mice (6.63±0.07 vs. 7.13±0.06, respectively). The difference was 
smaller in the presence of HCO3
-
 (6.96±0.03 vs. 7.18±0.04, respectively). Cre
-
 MLEC had similar 
basal pHi in the presence and absence of HCO3
-
.  
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The pHi of MLEC from VE-Cadherin
+
 animals did almost not recover after an ammonium prepulse 
and Na
+
-reintroduction in HEPES-buffered solutions. In the presence of HCO3
-
, the pHi still recovered 
much slower in MLEC from VE-Cadherin
+
 mice compared to cells from Cre
-
 mice. In contrast, MLEC 
from Cre
-
 animals recovered at a similar rate regardless of the presence of HCO3
-
.  
Taken together, these data confirm the absence of NHE1 in endothelial cells via its function on pHi 
regulation. They confirm results from HUVEC (see Figure 3-2) and are in agreement with a prominent 
role of NHE1 for the regulation of pHi in endothelial cells. Moreover, it can be concluded that in 
MLEC NHE1 is the main contributor to pHi recovery after acidification even in the presence of HCO3
-
. 
 
Figure 3-23: Endothelial cell-specific knockout of Nhe1 affects intracellular pH regulation 
Traces of pHi mesurements over time using the ammonium prepulse protocol in HEPES- (A) and HCO3
-
/CO2-
buffered (B) solutions are demonstrated. The graphs show the values for basal pHi (C) and the speed of recovery 
during the first 40 s after reintroducing Na
+
 (D). NHE1 is important to maintain basal pHi especially in the 
absence of HCO3
-
, and is crucial for pHi recovery after acidification both in HEPES- and HCO3
-
/CO2-buffered 
solutions. n=6coverslips/3mice for Cre
-
 in HEPES, n=5/3 for VE-Cadherin-Cre
+
 in HEPES, n=4/2 for Cre
-
 in HCO3
-
/CO2, n=3/1 for VE-Cadherin-Cre
+
 in HCO3
-
/CO2, n: the number of coverslips/mice;  Student’s t-test, p<0.05, § 
vs. Cre
-
 , # vs. VE-Cadherin-Cre
+
in HEPES. 
3.7.3 In vivo angiogenesis in the endothelial cell-specific Nhe1-/- mice - Matrigel 
plug assay 
After having demonstrated the specific knockdown of NHE1 in endothelial cells of Nhe1
flox/flox
; VE-
Cadherin-Cre
+ 
(VE-Cadherin
+
) mice on a protein level and on a functional level, in vivo angiogenesis 
was evaluated applying the Matrigel plug assay. VE-Cadherin
+
 and age-matched Cre
-
 littermates at the 
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age of 12-15 weeks were used. 500 µl Matrigel with or without VEGF were injected and 7 days later 
plugs were excised and analyzed as described in section 3.6.  
Figure 3-24 shows that in this series of experiments considerable angiogenesis was observed under 
basal conditions and VEGF had almost no additional effect on spouting regardless of whether NHE1 
was expressed in endothelial cells or not. The high basal vessel formation may be due to a higher 
content of growth factors in this batch of Matrigel compared to experiments in 3.6. The absence of 
NHE1 had no effect on basal sprouting. Currently, it is not clear whether this result is due to technical 
issues or whether it contradicts the data obtained in vitro and in constitutive Nhe1
-/-
 mice. 
 
Figure 3-24: Matrigel plug assay in endothelialc cell-specific Nhe1
-/-
 mice 
For this experiment 12-15 weeks old Nhe1
flox/flox
 (Cre
-
) and Nhe1
flox/flox
;VE-Cadherin-Cre
+
 (VE-Cadherin
+
) mice 
were used. 500 µl of Matrigel supplemented with or without VEGF (400 ng/ml) plus Heparin (400 µg/ml) was 
injected subcutaneously on either the right or the left flank, respectively. One week later, plugs were excised and 
angiogenesis was verified by immunofluorescence using an antibody against CD31. Quantification of vessel 
formation was done by evaluating eight different sections deriving from four different levels of each plug using 
the ImageJ software. A representative figure of a whole plug is given in (B), while a thresholded example of a 
magnified plug part (D) is given in (C). There was no VEGF-induced angiogenesis observed, and thus not 
difference between genotypes either. n=12 for Nhe1
flox/flox
, n=11 for Nhe1
flox/flox
;VE-Cadherin-Cre
+
, p<0.05, * vs. 
unstimulated, § vs. Nhe1
-/-
 VEGF, Two Way RM ANOVA. 
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4 Discussion 
The Na
+
/H
+
 exchanger NHE1 is a ubiquitously expressed plasma membrane protein that mediates the 
exchange of intracellular H
+
 for extracellular Na
+
, anchors actin filaments and has a scaffold function. 
Besides the general role in regulating intracellular pH and cell volume, NHE1 was shown to be 
involved in different processes such as migration, proliferation and survival. Although previous in 
vitro and in vivo studies point to NHE1’s importance in endothelial cells, its role in complex functions 
of the endothelium remains unexplored. This thesis was aimed at understanding NHE1 in endothelial 
cells; how it is regulated, its role in proliferation, survival, migration and in the complex process of 
angiogenesis. To this end, in vitro experiments were performed in mouse lung endothelial cells 
(MLEC) prepared from genetically modified mice and in primary human umbilical vein endothelial 
cells (HUVEC). Angiogenesis was also studied in vivo with constitutive Nhe1
-/-
 and endothelial cell-
specific Nhe1
-/-
 mice. The latter was generated during the course of this thesis and will be a useful 
model for future studies.  
The data of this thesis reveal that NHE1 is a major component of pH regulation in endothelial cells. It 
is involved in the regulation of growth factor-stimulated proliferation and migration and is regulated 
by hypoxia. NHE1 contributes to proangiogenic effects of VEGF in vitro and in vivo in constitutive 
Nhe1
-/-
 mice but the final proof of an angiogenic role in endothelial cell-specific Nhe1
-/-
 mice requires 
further experiments.  
4.1 Downregulation of NHE1 in endothelial cells 
In order to study the role of NHE1 in endothelial cells several tools had to be established. 
Downregulation of NHE1 in HUVEC by applying the RNAi technology was chosen as one approach 
to bypass the problems of specificity with pharmacological inhibitors and difficulties with 
overexpressing proteins in primary cells. A pool of four siRNA-sequences was selected, which 
allowed protein downregulation by approximately 75% and functional decline by 60% as detected by 
intracellular pH measurements, similar to what had been described previously [97].  The siRNA dose 
reaching maximal effects was lower (37 nM) than previously reported for the same siRNA pool [46, 
97]. 
4.2 Generation and verification of the endothelial cell-specific Nhe1-/- 
mouse 
Additional important tools to study the role of NHE1 in endothelial cells are mouse models, in which 
the protein is genetically ablated. In these mice, vascular phenotypes can be characterized under basal 
conditions and upon challenge. In addition, primary endothelial cells can be isolated and investigated 
with the advantage of a complete absence of the protein in comparison to protein downregulation via 
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RNAi strategies. The constitutive Nhe1
-/-
 mouse, which was already available in the laboratory, has a 
short life span, which limits its usage for functional tests and preparation of cells. In addition, the data 
obtained in these mice are difficult to be attributed to endothelial NHE1. Thus, one aim of this study 
was to generate endothelial cell-specific Nhe1
-/-
 mice to specifically investigate the function of NHE1 
in endothelial cells.  
In order to characterize specific knockout of the NHE1 protein in murine endothelial cells, methods to 
evaluate NHE1 expression were required. The detection of NHE1 in murine tissues was technically 
challenging. None of the antibodies tested (sc-136239 Santa Cruz; NHE11-A, Alpha Diagnostik; 
mab3140, Millipore; sc-28758, Santa Cruz) showed a specific staining for NHE1 in the mouse tissues 
when compared to the constitutive Nhe1
-/-
 mouse tissues (brain, heart, kidney and liver; data not 
shown). Thus, gene knockout had to be verified in isolated MLEC. Here, the purity of the cultures 
revealed to be a critical point for western blot analyses. Contamination of MLEC with non-endothelial 
cells of more than 20% seemed sufficient to cause false positive NHE1 signals in western blots. 
Therefore, analyses of cells by flow cytometry was established, where the endothelial marker CD31 
was additionally stained to determine NHE1 signal specifically from endothelial cells. Fortunately, 
one anti-NHE1 antibody (NHE11-A, Alpha Diagnostik) that failed to specifically stain the protein in 
the tissue, showed specific reactions in flow cytometry analysis of isolated cells. This was proven by a 
clear difference between MLEC from wild type mice and the constitutive Nhe1
-/- 
mice.  
At first, Nhe1 gene-knockout in endothelial cells was attempted with a Tie2-Cre-recombinase
+
 line, in 
which the expression of Cre-recombinase is driven by an endothelial-specific promoter/enhancer, 
which encodes the angiopoietin receptor Tie2 [98].  Experiments of this study had shown that this line 
successfully recombined a Tomato-floxed knockin gene [99]. However, the Nhe1-floxed gene was not 
efficiently recombined, probably because the Nhe1 gene locus is more difficult to access than the 
Rosa26 locus, in which the gene for the Tomato fluorescent protein was inserted. Thus, western blot 
and flow cytometry analyses did not show differences in NHE1 expression between MLEC deriving 
from the Nhe1
flox/flox
; Tie2-Cre
+
 line and the Nhe1
flox/flox
 line. 
As a second attempt, another endothelial-specific Cre line, the VE-Cadherin-Cre-recombinase
+
 line 
[97], was employed. Mating mice of this Cre line with mice from the Nhe1-floxed line led to the 
generation of a Nhe1
flox/flox
;VE-Cadherin-Cre
+
, in
 
which
 
the absence of NHE1 in isolated endothelial 
cells was clearly proven by different approaches. Flow cytometry analyses showed no NHE1 staining 
in CD31-positive cells whereas the CD31-negative cells expressed normal levels of the protein. This 
difference was not only shown in cells, which were cultured up to 12 days, but also in cells that were 
kept in culture shorter than two days. Thus, the possibility of recombination occurring in vitro during 
culturing was excluded. Gene knockout was also confirmed by western blot analysis of high purity 
(>95%) MLEC cultures, and functionally proven by intracellular pH measurements.  
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Taken together, mating the Nhe1-floxed line (generated by Dr. Christopher Hennings) with the VE-
Cadherin-Cre
+
 line, but not with the Tie2-Cre
+
 line, enabled the generation of endothelial cell-specific 
Nhe1
-/-
 mice. The mice were viable and grew normally without any of the obvious phenotypes 
described for the constitutive Nhe1
-/-
 mice.  
4.3 NHE1 is important in regulating endothelial cell intracellular pH 
Measurements of intracellular pH in primary endothelial cells prepared from endothelial cell-specific 
Nhe1
-/-
 mice as well as in HUVEC, in which NHE1 was downregulated, were performed in this study 
to understand the role of NHE1 in intracellular pH regulation. In addition, these experiments served to 
prove NHE1 knockout on a functional level (Figure 3-23).  
The data obtained in primary murine Nhe1
-/-
 endothelial cells suggest that NHE1 is the most important 
bicarbonate-independent acid extruder in endothelial cells. When NHE1 was knocked out, steady-state 
pHi and recovery after cytoplasmic acidification were drastically reduced in bicarbonate-free buffered 
solutions. In the presence of bicarbonate, steady-state pHi was only slightly reduced while recovery 
was still much slower, approximately fivefold. Therefore, whereas the bicarbonate-dependent 
transporters may play a role in the control of steady-state intracellular pH, NHE1 seems to be the 
prominent acid-extruder after acidification even in the presence of bicarbonate.  
Similar results were observed after downregulation of NHE1 with siRNA in HUVEC, since the 
differences of intracellular pH and recovery rate compared to control cells with unchanged NHE1 
levels were lower. NHE1-depleted cells recovered their pHi at a 60% slower rate. The remaining 
ability to recover could be explained by maximal activation of residual NHE1 protein since 
downregulation was not complete. Given that the NHE1 inhibitor EIPA abolished pHi recovery both in 
control siRNA- and NHE1-siRNA treated cells (Supplementary 1), it can be speculated that no other 
NHE isoform, especially NHE2, compensates for NHE1 in endothelial cells. The discrepancy between 
the effects of NHE1 knockout and knockdown underlines the importance of knockout models, in 
which the consequences of NHE1 depletion can be seen more clearly. This has also to be considered 
when interpreting the functional data obtained in cells, in which NHE1 is downregulated by siRNA. 
The recovery rate of approximately 0.5 pH units/min that was observed in this study is similar to what 
has previously been reported in cultured endothelial cells [73]. Our findings are also in agreement with 
recent publications, in which regulation of intracellular pH was analyzed in situ on arteries from 
constitutive Nhe1
-/-
 [17] and Nbcn1
-/-
 [16] mice. Both studies identified NHE1 as the main bicarbonate-
independent acid-extruding transporter in acidified endothelial cells even in the presence of 
bicarbonate while the Na
+
/HCO3
-
 cotransporter NBCn1 was the major bicarbonate-dependent 
mechanism. The steady-state pHi values in these experiments seemed to be slightly higher [17] or 
lower [16] compared to the values seen in the current study (~ 7.2). This could be explained by the 
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different mouse strain used. As reported in the literature, the steady-state pHi of endothelial cells 
ranges from 7.05 to 7.35 pH units depending on the genetic background of the mouse strains (NMRI, 
FVB, C57BL/6J) [107].  
The contribution of NHE1 compared to NCBn1 in maintaining the steady-state pHi is not uniformly 
discussed in the literature. In the two studies mentioned above [16, 17], NHE1 participation in the 
regulation of steady-state pHi was small compared to bicarbonate-dependent transporters. In the 
current study, bicarbonate removal from the medium did not reduce the steady-state pHi of endothelial 
cells that express NHE1 while Nhe1
-/-
 MLEC had a lower steady-state pHi even in the presence of 
bicarbonate. These findings highlight NHE1 as important in maintaining steady-state pHi and 
contradict the hypothesis of a low contribution of NHE1 to steady-state pHi regulation. Several hints 
from the literature support the finding of this study that NHE1 is active in the physiological range of 
steady-state pHi. For instance, NHE1 was compensatory activated in NBCn1
-/-
 endothelial cells [16, 
17] and pharmacological inhibition of NHE1 prevented an increase of pHi induced by bicarbonate 
removal [107]. However, besides the difference in mouse strains used, other variations in the 
experimental settings between the individual studies should also be considered. Whereas in this thesis 
cultured lung microvascular endothelial cells were used, the three publications mentioned above 
describe pHi measurements in situ in mesenteric artery endothelial cells. Also, the methods of 
measuring recovery rates were different compared to the current work since in situ cells were acidified 
by superfusing with Na
+
-free buffered solution, instead of ammonium prepulse technique. 
In summary, our data together with literature data suggest that NHE1 and NBCn1 are the two 
important acid-extruding ion transporters in endothelial cells under steady-state conditions, while 
NHE1 mediates most of the proton extrusion at sub-physiological pH during the recovery of 
intracellular pH. 
4.4 NHE1 supports endothelial cell proliferation without affecting survival 
The ability of NHE1 to regulate global cytoplasmic pH and cell volume by exchanging hydrogen and 
sodium ions implicates it in homeostasis during cell proliferation. To test whether this applies to 
endothelial cells, NHE1 was silenced in HUVEC and proliferation was analyzed by monitoring cell 
numbers and cell cycle distribution. The effect of NHE1 downregulation was tested in two 
experimental settings, one was cell proliferation in growth factor-rich medium and the other one was 
VEGF-induced proliferation in serum-poor medium applying the same experimental schedule as in the 
spheroid assays. The obtained data show that NHE1 knockdown reduced endothelial cell proliferation 
by 35% in growth factor-rich medium, probably by blocking the cells in the G0/G1 phase of the cell 
cycle. Under this condition cell survival was not altered. Stimulation of control endothelial cells with 
VEGF led to only a moderate increase of proliferation, which is in line with previous observations 
from the laboratory and other groups [5, 108]. In contrast, VEGF had strong antiapoptotic effects. 
4 Discussion 
66 
 
When NHE1-depleted cells were stimulated with VEGF, proliferation was lower than in NHE1-
containing cells. Basal and VEGF-induced survival were not affected by NHE1 knockdown, though. 
So far, few studies indicate that NHE1 is important in endothelial cell proliferation. Yu et al. [109] 
showed that silencing NHE1 with siRNA inhibited human pulmonary artery endothelial and vascular 
smooth muscle cell proliferation by approximately 35%, probably as a consequence of cell arrest in 
G0/G1 phase, similarly to our observations. At least for smooth muscle cells, the authors suggested that 
the loss of NHE1 inhibits E2F1-dependent transcription of genes that control proliferation by 
increasing p27 (a cyclin-dependent kinase inhibitor). No information was provided on growth factors 
used, time frames and other experimental procedures though. Another study similarly showed that 
NHE1 siRNA reduced endothelial cell proliferation, whereas VEGF rescued the effect [88]. 
Endothelial proliferation is stimulated primarily via the ERK and PI3K/Akt pathways [110]. Since 
NHE1 has been reported to regulate MAPKs, NHE1 knockdown could inhibit proliferation by 
affecting MAPK-triggered proliferative pathways. The mechanisms linking NHE1 to MAPK 
regulation are not clear but may include roles of the transported ions and conformational coupling of 
NHE1 to enzymes or cytoskeletal elements and seem to be highly cell- and context-specific [111]. 
Regulation of MAPK by NHE1 has not been investigated in endothelial cells so far. The data of this 
study show that at least in response to VEGF, ERK1/2 phosphorylation is not altered in NHE1-
depleted cells suggesting that ERK1/2 inhibition may not mediate the effects of NHE1 downregulation 
on proliferation. However, several proteins involved in the regulation of cell cyle and proliferation are 
pH sensitive and may contribute to the observed effects. One such example is ROCK, whose activity 
was decreased at low pH [16]. Therefore, since ROCK is known to be required for G1-S phase 
transition of the cell cycle [112], a decrease in ROCK activity could be responsible for the observed 
cell cycle block in the G0/G1 phase.     
NHE1 has also been shown to regulate the activation of the PI3K/AKT pathway and consequently cell 
survival. It has been reported that when renal proximal tubule epithelial cells were subjected to 
apoptotic stress, NHE1 acted as a scaffold for phosphorylated ezrin/radixin/moesin and 
phosphatidylinositol 4,5-bisphosphate [69] resulting in activation of the pro-survival kinase AKT [72]. 
However, in the current study neither VEGF-induced AKT phosphorylation nor VEGF-triggered 
survival was affected by NHE1 knockdown, which again may point to cell-specificity of NHE1 effects 
described in the literature.  
In conclusion, the results of this study provide evidence that NHE1 supports endothelial cell 
proliferation probably by facilitating progression through the G0/G1 phase of the cell cycle, whereas it 
does not affect survival of endothelial cells. It remains to be clarified whether this is due to actin 
anchoring and scaffolding functions of NHE1 as well, or is limited to the ion exchange activity. 
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4.5 NHE1 supports endothelial cell chemotaxis 
During angiogenesis, endothelial cells migrate in response to a cocktail of chemotactic factors, which 
trigger their invasion into the ischemic tissue. Although previously overexpression studies have shown 
overexpressed NHE1 to localize at the leading edge of migrating cells [39, 49], or native NHE1 in 
neocortical growth cones [113], the results of this study describe for the first time co-staining of native 
NHE1 and actin at cell protrusions of single endothelial cells migrating sporadically while NHE1 was 
localized at cell-cell contacts in confluent endothelial monolayers. Since localization in these plasma 
membrane domains pointed to a role of NHE1 in mediating cell migration, three different migration 
assays were employed in HUVEC: wound healing, transwell and chemotaxis assay. The chemotaxis 
assay mimics the conditions in vivo and allows real time tracking of cell movement towards the 
gradient of the stimulus. 
In all the three assays, S1P strongly induced endothelial cell migration while VEGF failed to stimulate 
cell mobility under all conditions. Knockdown of NHE1 affected S1P-induced migration in the applied 
test systems. It reduced migration through transwell membranes and attenuated wound closure. 
Furthermore, NHE1-depleted cells moved slightly slower and could not properly orient in the parallel 
axis of the chemotactic gradient, which reduced the net movement towards S1P by 32% in the 
chemotaxis assay. Together, these data identify NHE1 as a pro-migratory factor in endothelial cells. 
The exceptional potency of S1P as a migratory stimulus compared to VEGF is described in previous 
reports. Liu et al. [104] described S1P as four times more potent as VEGF in a transwell migration 
assay designed similarly to ours. Moreover, besides the argument that S1P is more potent than VEGF 
in inducing endothelial cell migration, the response to the stimulus might differ among endothelial 
cells from different tissue origin. For instance, VEGF stimulated-migration was sixfold higher in 
pulmonary artery endothelial cells than in lung microvascular endothelial cells [104].  
Two publications directly involved NHE1 in endothelial cell migration. Bussolino et al. [34] evaluated 
the effect of pharmacological inhibition of NHE1 with EIPA on endothelial cell migration in response 
to granulocyte- and granulocyte-macrophage-colony-stimulating factor. In agreement with the current 
study the authors showed inhibitory effects of EIPA on endothelial migration although relatively high 
concentrations of EIPA were required (10 and 50 µM). In contrast, in the current study 0.5 µM EIPA 
were sufficient to completely block intracellular pH recovery after an ammonium prepulse 
(Supplementary 1). Pharmacological inhibition should only affect the ion exchange activity of NHE1 
and not influence actin binding suggesting that NHE1 controls migration via pHi regulation. The 
siRNA approach applied in the current study would affect all NHE1 functions and leave the question 
open of whether ion transport or cytoskeletal regulation are important for NHE1-mediated migration. 
In the study of Mo et al. [88], a pro-migratory role of NHE1 was also seen although under different 
conditions compared to the current experiments. The authors observed that overexpression of HIF1 
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induced proliferation, migration and tube formation and that this was inhibited by NHE1 
downregulation. The effect of NHE1 was attributed to maintaining calpain activity required for 
angiogenic processes probably by maintaining pH homeostasis.  
NHE1 was extensively studied in migration of other cell types and the current results contribute to the 
few data on its involvement in endothelial cell migration. All three employed assays highlight a 
supportive role of NHE1 in S1P-induced migration of endothelial cells. It remains to be clarified 
whether this is a general effect on cell migration or specific to S1P stimulation. However, S1P is 
known to be a potent angiogenic signaling molecule and is involved in crosstalks with VEGF 
signaling pathways [9, 114]. For instance[114], an S1P1 receptor-selective antagonist inhibited VEGF-
induced angiogenesis in a corneal model [9] and VEGF has been shown to upregulate S1P1 receptors 
in endothelial cells [115]. S1P has been shown to stimulate migration and angiogenesis mainly 
through S1P1 receptor and the activation of the small GTPase Rac [9]. The complete process of 
migration, however, requires coordinated actions of Rac and the Rho/ROCK system. Interestingly, 
tissue analysis from Nhe1
-/-
 mice showed reduced protein and mRNA level of ROCK1 and ROCK2, 
which would be one explanation of how NHE1 could inhibit S1P-induced migration through Rho 
GTPase signaling [76]. In addition, ROCK activity is regulated by pHi and was decreased at low pH 
[16]. NHE1 may also act downstream of RhoA to modulate initial steps in integrin signaling for the 
assembly of focal adhesions [116].  
The current migration experiments were performed in 2D systems, in which important players of 
migratory response, the matrix metalloproteinases, are probably of minor importance. Proteolytic 
activity required for digestion of extracellular matrix, however, has been reported to be pH-dependent. 
In particular, localized NHE1 activity can decrease the extracellular pH near the plasma membrane 
and optimize matrix metalloproteinase digestive activity [56]. For instance, inhibiting the NHE1 or 
lowering extracellular pH has been shown to increase protease secretion and promote proteolysis in 
the peri-invadopodial microenvironment of tumor cells [56]. Therefore, NHE1 involvement in 
endothelial cell migration in an experimental 3D structure, for instance in Matrigel, or in vivo could be 
even more profound than the current in vitro data suggest [117, 118]. 
4.6 The role of NHE1 in angiogenesis 
Proliferation and migration are two major processes required for angiogenesis. Since NHE1 was 
involved in the regulation of endothelial cell proliferation and chemotaxis, we expected its 
participation in the regulation of angiogenesis. Indeed, the results of this thesis suggest that NHE1 is a 
pro-angiogenic factor although unequivocal evidence is lacking. 
In an in vitro approach, the spheroid assay, VEGF potently induced sprouting of HUVEC spheroids, 
although it had been a weak inducer of proliferation and did not affect HUVEC migration in the 
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current study. Probably, the simultaneous stimulation of several functional processes in a 3D system 
was required to induce a full angiogenic effect. Downregulation of NHE1 in HUVEC by siRNA 
inhibited VEGF-induced sprouting by 56%. Accordingly, in vivo studies in a Matrigel plug assay in 
constitutive Nhe1
-/-
 mice showed an inhibition of VEGF-triggered vascularization. Both findings point 
to a pro-angiogenic function of NHE1, which could be attributed to mechanisms discussed above (see 
1.4 and 1.5) and to additional effects on pH-sensitive pro-angiogenic molecules such as eNOS [16]. 
However, when the endothelial cell-specific Nhe1
-/-
 mice became available and the Matrigel plug 
assay was repeated in these mice, the obtained result did not confirm the previous observation. This 
was mainly due to a lack of a proangiogenic VEGF effect in both, control and endothelial cell-specific 
Nhe1
-/-
 mice. 
The reason for the discrepancy of results between constitutive and endothelial-specific Nhe1
-/-
 mice is 
not clear but two major differences between the two experimental series are apparent. Although all 
mice were of the C57BL/6J genetic background, endothelial cell-specific Nhe1
-/-
 animals were 12-15 
weeks old, whereas the assay with constitutive Nhe1
-/-
 animals was performed with 10-16 days old 
mice due to the severe phenotype and early death of the animals. Also, as expected, constitutive Nhe1
-
/-
 mice exhibited growth retardation (data not shown) and it is not clear how this has affected the 
outcome of the assay. However, although the younger mice may have a better angiogenic potential in 
response to VEGF, the age difference would not explain the absence of VEGF effect in the older 
animals since our group has previously observed a robust VEGF-induced angiogenesis in mice of 
similar age [119].  
Another variation between the two series of angiogenesis assays was that different Matrigel batches 
were used. Matrigel is an extract of extracellular matrix from mouse sarcomas, and despite processing 
to reduce its growth factor content, batches may differ and the remaining growth factors could cause 
high basal angiogenesis in the absence of VEGF. Indeed, in average, basal vascularization in the plugs 
from endothelial cell-specific Nhe1
-/-
 mice seemed to be higher when compared to plugs from 
constitutive Nhe1
-/-
 mice and VEGF was not able to induce further significant angiogenesis regardless 
of which mice were tested. Thus, to repeat the experiment with another Matrigel batch and/or to test 
angiogenesis in parallel in equally old constitutive and endothelial cell-specific Nhe1
-/-
 mice could 
probably clarify how the discussed variables have influenced the outcome of the assay.  
It is also possible that the effect of Nhe1 knockout observed in the constitutive Nhe1
-/-
 mice is not only 
dependent on the absence of NHE1 in endothelial cells. Angiogenesis is considerably affected by 
factors secreted from hematopoietic and mural cells suggesting that Nhe1 knockout in these cells could 
play an additional role. In line with this NHE1 has been shown to promote VEGF secretion from 
leukemia cells [120]. Thus, the constitutive absence of NHE1 could alter the microenvironment of 
newly formed capillaries in a detrimental way. However, when staining cell nuclei in the plug 
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sections, almost all nuclei were co-stained with CD31 signal suggesting that only few non-endothelial 
cells were immigrated into the Matrigel plugs. Against this background, the suitability of the Matrigel 
assay for testing NHE1 functions in vivo could be questioned, since it uses an artificial matrix and 
provides limited options for physiologically important cell-cell interactions.  
Taken together, in vitro and in vivo assays support the hypothesis that NHE1 in endothelial cells 
promotes angiogenesis. Studies in endothelial cell-specific Nhe1
-/-
 mice were not conclusive since no 
pro-angiogenic effects in response to VEGF were seen, possibly due to methodological problems. 
Further studies, probably including more physiological angiogenesis assays, with endothelial cell-
specific Nhe1
-/-
 mice need to be performed.  
4.7 Hypoxia induces NHE1 expression by HIF2α-dependent mechanisms 
The results of this study show that endothelial cells exposed to hypoxia (1% O2 experimentally) 
upregulate NHE1 expression. In parallel, the transcription factors HIF1 and HIF2 accumulated. 
Using RNAi technology to downregulate both hypoxia-induced transcriptions factors it could be 
demonstrated thatHIF2 but not HIF1 was responsible for the induction of NHE1 protein. NHE1 
expression was also increased in response to the chemical HIF inducer cobalt chloride. 
Both HIF1α and HIF2α are co-expressed in a large number of cell types and exhibit overlapping 
functions but also unique and sometimes opposing activities [121]. HIF2 seems to be particularly 
abundant in blood vessels and may accumulate at higher levels of O2 than HIF1. Both transcription 
factors lead to expression of the glucose transporter GLUT1 and VEGF. HIF1 seems to specifically 
target genes encoding for glycolytic enzymes while HIF2 triggers expression of arginase, TGF, 
angiopoietin 2 and delta-like protein 4, a ligand for the NOTCH receptor, to name a few. NHE1 has 
already been shown to be upregulated by hypoxia [73]. An involvement of HIF1 in NHE1 induction 
was suggested based on overexpression studies [88, 89] but no detailed analyses on the involvement of 
endogenously expressed HIF1 or HIF2 were performed. The current study suggests that NHE1 
gene- or protein-regulating factors may represent targets of HIF2. How this fits into the general 
pattern of HIF2 target genes and how it may help to understand the angiogenic role of NHE1 remains 
to be investigated. 
The pathophysiological reason for the induction of NHE1 in endothelial cells is not clear but may be 
related to an upregulation of glycolysis in endothelial cells under hypoxic/ischemic conditions. The 
higher rate of glucose consumption would lead to an increase of the production of acid equivalents 
similar to ischemia and require higher NHE1 activity. Interestingly, results of this thesis show that 
hypoxia induction of NHE1 was diminished when changing medium every 24 h. Since the new 
medium was preincubated for pH, O2 and temperature equilibration, the effect could have either 
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resulted from the removal of secreted factors into the supernatant or supplementation of the 
supernatant for the degraded factors. Therefore, HIF2 may directly act as a transcriptional factor on 
the NHE1 promoter, but it may also indirectly influence NHE1 protein expression or degradation.  
Cutaia et al. [73] has shown that hypoxia induced NHE1 protein levels in endothelial cells after 72 h, 
whereas mRNA levels remained comparable to the normoxic control. Therefore it is possible that 
HIF2 regulates NHE1 expression post-translationally by promoting factors, which negatively 
regulate NHE1 degradation. For instance, one study on breast cancer showed that EGF increased 
NHE1 expression by inhibiting protein degradation [122]. ROS have also been linked to NHE1 
regulation whereby O
2-
 increased expression and H2O2 decreased its expression [87]. Thus, it is 
possible that hypoxia-induced ROS could affect NHE1 protein levels. Given that different ROS could 
have opposing effects, such experiments would need to be carefully designed the more so that ROS 
such as H2O2 were shown to inhibit NHE1 activity in endothelial cells [75].  
In conclusion, the results of this study show that NHE1 protein levels increase during hypoxia via 
HIF2-dependent mechanisms. Future studies should test whether increased expression is paralleled 
by enhanced NHE1 activity. These findings should be considered in terms of NHE1’s role in 
endothelial cells during angiogenesis and wound healing, vascular tone [17], atherosclerosis [31, 32], 
and ischemia/reoxygenation induced tissue damage. 
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5 Conclusions and Outlook 
Angiogenesis is a complex process controlled by various intracellular mechanisms, growth factors and 
changes in the tissue microenvironment. The current study suggests a proangiogenic role for the 
Na
+
/H
+
 exchanger NHE1, which adds to our understanding of its importance in endothelial cells and 
the vasculature. However, several limitations have to be considered. Firstly, the angiogenesis assay 
employed during this study, the matrigel plug assay, does not sufficiently mimic changes in the 
microenvironment that occur in the ischemic tissue during angiogenesis. Moreover, the constitutive 
Nhe1
-/-
 mice, in which the effect of NHE1 on VEGF-induced angiogenesis was observed, have a 
severe phenotype that could potentially influence the outcome of the in vivo results. And finally, the 
ultimate evidence from the endothelial cell-specific Nhe1
-/-
 mice is still lacking. In any case, given that 
the differences of VEGF-induced angiogenesis between constitutive Nhe1
-/-
 and wild type mice was 
moderate, NHE1 may belong to permissive proangiogenic factors rather than being an essential one. 
The efficient Nhe1 knockout in the endothelial cell-specific Nhe1
-/-
 mice is, however, very 
encouraging to further discern the role of NHE1 in the endothelium. Hypoxia-induced NHE1 
expression may potentiate its proangiogenic role in the acidic and hypoxic microenvironment during 
ischemia-induced angiogenesis. This may be relevant during tumor angiogenesis, the more so that 
NHE1 inhibitors were shown to inhibit tumor growth [123] and may impair inflammatory processes 
[86, 93, 124-126]. Pharmacological inhibition of NHE1 could be beneficial by synergistically 
targeting several cell types. Therefore, other models better mimicking physiological and 
pathophysiological angiogenesis, like the hind limb ischemia model and tumor angiogenesis models 
could provide clearer insights into the role of NHE1 in this process. 
Besides angiogenesis, the newly generated endothelial cell-specific Nhe1
-/-
 mice could be useful in 
analyzing NHE1´s role in other vascular functions. As described in Boedtkjer et al. [17], the artery 
walls of the constitutive Nhe1
-/-
 mice were thinner and mice had low arterial blood pressure compared 
to the wild type littermates. Since this phenotype could also be related to Nhe1 knockout in vascular 
smooth muscle cells it would be interesting to analyze whether the endothelial cell-specific Nhe1
-/-
 
mice show the same phenotype. These mice could be used in stroke models as well, where NHE1 
inhibition preserved the endothelial cell barrier, which reduced brain edema and tissue damage. Our 
preliminary results show that NHE1 downregulation in endothelial cells reduced PAI-1 expression. 
This might be an interesting finding since clinical trials to treat cardiomyopathies with NHE1 
inhibitors were stopped as a result of increased incidence of thromboembolic strokes [82, 127]. 
Finally, a lot of effort has been made to develop specific pharmacological inhibitors of NHE1. Many 
of them have been studied in clinical trials and valuable experience on their pharmacokinetic and 
toxicological properties is available. Therefore, understanding the role of NHE1 in vascular tissue is of 
5 Conclusions and Outlook 
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potential clinical significance. For instance, NHE1 inhibitors seem to be promising anticancer agents 
in a wide array of malignant tumors and leukemias. Against this background, their influences on the 
vasculature and their potential vascular side effects have to be clarified. However, translating mouse 
studies with genetic deletion of Nhe1 into pharmacological inhibition in the clinics needs to be done 
cautiously, since the pharmacological inhibition mainly affects the ion exchange activity, whereas the 
knockout of NHE1 in mice affects all the functions of the protein. 
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7 Supplementary 
 
Supplementary 1: Intracellular pH measurements in HUVEC after inhibition with EIPA 
Traces of pHi measurements in HEPES-buffered solutions after inhibition with 0.5 µM EIPA show inhibition of 
pHi recovery after acidification with ammonium prepulse protocol in both CsiR and NsiR HUVEC. n=3 for CsiR 
(scRNA transfected HUVEC), n=1 for NsiR (NHE1 siRNA transfected HUVEC) 
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